[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 539
1. Hughes NR, Goodman ZD, Bhathal PS: An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis. Am J Surg Pathol; 2010 Sep;34(9):1312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we compare the expression of 13 tissue antigens in bile duct adenomas, other benign bile duct lesions, and various foregut-derived tissues, to further investigate the bile duct adenoma phenotype and pathogenesis.
  • 1F6 and MUC6 were normally present in bile ductules and canals of Hering, whereas the epithelium lining the larger bile ducts stained focally for D10, MUC5AC, MUC6, or TFF2 in, respectively, 21%, 36%, 43%, and 100% of the livers examined.
  • Focal expression of MUC6, or TFF2 was observed in 1 or 2 examples of 14 von Meyenburg complexes and 6 polycystic livers, with staining for acid mucin generally obvious only in the glycocalyx of the epithelium of these two types of lesions.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Intestines / metabolism. Intestines / pathology. Liver / metabolism. Liver / pathology. Male. Middle Aged. Mucins / metabolism. Phenotype. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679879.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


2. Medina EA, Arias VL: [Middle ear adenoma]. Biomedica; 2009 Sep;29(3):348-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, a middle ear neoplasm is described that became apparent because of its appearance in the external ear duct as it protruded from the middle ear through the eardrum.
  • Following resection, the specimen was determined to be a benign epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436986.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  •  go-up   go-down


3. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W: Precursors of endometrial clear cell carcinoma. Am J Surg Pathol; 2006 Dec;30(12):1519-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recognition of morphologically identifiable lesions which may confer an increased risk for subsequent development of an invasive malignancy offers an opportunity to investigate and better understand the molecular-genetic etiopathogenesis of the well-developed tumor, and potentially, to administer a therapeutic intervention before its development.
  • Thirty-eight benign uteri and 30 uteri with classic endometrial endometrioid carcinoma (EEC) served as controls.
  • The lesions were typically isolated glands or surface epithelium (within an otherwise normal endometrial region) that displayed cytoplasmic clarity and/or eosinophilia with varying degrees of nuclear atypia.
  • In contrast, PPL were identified neither in the benign uteri nor in endometrioid carcinoma control groups (P<0.001).
  • The immunohistochemical expression of p53, mib-1, estrogen receptor (ERs), and progesterone receptor in the benign endometria, ECCC, and the PPL were evaluated on all 27 cases.
  • The mean p53 scores for the benign endometria, PPL, and ECCC were 0, 4.5, and 6.2, respectively.
  • ER/progesterone receptor indices for benign endometria, PPL, and carcinoma were 90/80, 21.52/4.61, and 11/4, respectively.
  • The PPL described herein have a morphologic and immunophenotypic profile which seems to be distinct from both the benign endometria in which they reside and the adjacent areas of ECCC.
  • The high frequency of association of these lesions with ECCC, their frequent occurrence as isolated lesions within otherwise "benign-appearing" endometria, and their continuous spectrum of nuclear atypia from minimum (grade 1, cytologic atypia falls short of ECCC cells) to maximum (grade 3, cytologically identical to ECCC cells), argues in favor of our hypothesis that these may represent precursor lesions of ECCC.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Endometrium / chemistry. Endometrium / pathology. Exocrine Glands / chemistry. Exocrine Glands / pathology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Single-Blind Method

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122507.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Song YS, Park CK: Squamous epithelial-lined cyst occurring in an aneurysmal fibrous histiocytoma. Am J Dermatopathol; 2007 Jun;29(3):309-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous epithelial-lined cyst occurring in an aneurysmal fibrous histiocytoma.
  • [MeSH-major] Cysts / pathology. Epithelium / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Leg. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519635.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Zembowicz A, Garcia CF, Tannous ZS, Mihm MC, Koerner F, Pilch BZ: Endocrine mucin-producing sweat gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas. Am J Surg Pathol; 2005 Oct;29(10):1330-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, they were well-circumscribed, typically multinodular tumors with solid or partially cystic nodules, frequently showing areas of papillary architecture.
  • The nodules were formed by uniform small- to medium-sized oval to polygonal epithelial cells with lightly eosinophilic to bluish cytoplasm.
  • All tumors examined immunohistochemically expressed at least one neuroendocrine marker, synaptophysin or chromogranin.
  • All tumors tested expressed estrogen and progesterone receptors, cytokeratin 7, low molecular cytokeratin Cam5.2, and epithelial membrane antigen and were negative for cytokeratin 20 and S-100 protein.
  • Calponin, smooth muscle actin, and p63 immunohistochemical stains did not disclose myoepithelial cells around larger tumor nests in most cases, supporting the notion that EMPSGC is an invasive carcinoma.
  • In 10 cases, cystic areas lined by benign epithelium indistinguishable from eccrine ducts were present.
  • In some foci, the benign ductal epithelium was undermined or replaced by carcinoma in situ with similar cytologic features to the solid or papillary areas of EMPSGC.
  • The series provides histologic evidence for a multistage progression of noninvasive sweat gland neuroendocrine carcinoma to EMPSGC and then to mucinous carcinoma of the eyelid.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cheek / pathology. Eyelid Neoplasms / metabolism. Eyelid Neoplasms / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE: Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer; 2007 Jun 1;120(11):2426-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we report that the expression of immunoreactive NGAL (irNGAL) in ovarian tumors changes with disease grade and that this change is reflected in the concentration of NGAL in peripheral blood.
  • A total of 59 ovarian tissues including normal, benign, borderline malignant and grades 1, 2 and 3 malignant were analyzed using immunohistochemistry. irNGAL was not present in normal ovaries and the NGAL expression was weak to moderate in benign tissues.
  • Both borderline and grade 1 tumors displayed the highest amount of NGAL expression with moderate to strong staining, whereas in grade 2 and 3 tumors, the extent of staining was significantly less (p < 0.01) and staining intensity was weak to moderate.
  • Staining in all cases was confined to the epithelium.
  • Compared to control samples, the NGAL concentration was 2 and 2.6-fold higher in the serum of patients with benign tumors and cancer patients with grade 1 tumors (p < 0.05) and that result was consistent with the expression of NGAL performed by Western blot.
  • Moderate to strong expression of NGAL was observed in epithelial ovarian cancer cell lines SKOV3 and OVCA433 while no expression of NGAL was evident in normal IOSE29 and mesenchyme-like OVHS1, PEO.36 and HEY cell lines.
  • These data indicate that NGAL may be a good marker to monitor changes of benign to premalignant and malignant ovarian tumors and that the molecule may be involved in the progression of epithelial ovarian malignancies.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Epithelium / pathology. Mesoderm / pathology. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Biomarkers. Blotting, Western. Cell Line, Tumor. DNA Primers. Electrophoresis, Polyacrylamide Gel. Female. Humans. Immunohistochemistry. Lipocalins. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294443.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers; 0 / DNA Primers; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


7. Streitz JM Jr, Madden MT, Marimanikkuppam SS, Krick TP, Salo WL, Aufderheide AC: Analysis of protein expression patterns in Barrett's esophagus using MALDI mass spectrometry, in search of malignancy biomarkers. Dis Esophagus; 2005;18(3):170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We postulate that direct analysis of epithelial proteins using mass spectrometry will provide protein profiles capable of identifying patients at high risk of developing malignancy.
  • Our aim is to find transitional protein signals that show a cancer profile within histologically benign BE, which can be used as indicators of early malignant change.
  • Samples of squamous epithelium, and both benign and malignant Barrett's epithelium, were compared for differences in protein expression.
  • Reliable differentiation of squamous and Barrett's epithelium was demonstrated.
  • A comparison of benign and malignant Barrett's epithelium identified a number of cancer-specific protein peaks that were deletion or expression variations from benign epithelium.
  • In four instances the proteins (7350, 8446, 10850, and 14693) appeared to be early malignant changes in histologically benign BE.
  • Mass spectrometry performed upon fresh-frozen Barrett's epithelium, obtained by laser-capture microdissection, displays reproducible, tissue-specific, protein profiles.
  • Distinct differences are demonstrated between benign and malignant epithelium, some of which appear to be candidate biomarkers of early malignant change.
  • This technique reliably displays cellular protein expression in esophageal epithelium and deserves further study as a tool to identify early malignant degeneration in BE.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045579.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Valdman A, Fang X, Pang ST, Nilsson B, Ekman P, Egevad L: Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol; 2005 Nov;48(5):852-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ezrin expression in prostate cancer and benign prostatic tissue.
  • METHODS: Immunohistochemical analysis was used to characterize patterns of ezrin expression in prostatic carcinoma and benign epithelium in 103 radical prostatectomy specimens.
  • RESULTS: Ezrin IR in prostate cancers was moderate or strong in 70% of specimens while negative or only weakly positive in benign epithelium.
  • Epithelium of seminal vesicles and ejaculatory ducts was always intensely positive.
  • Interestingly, high levels of ezrin IR were observed in benign metaplastic epithelium and in seminal vesicles.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prostatectomy. Statistics as Topic

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230228.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / ezrin
  •  go-up   go-down


9. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K: Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res; 2008 Sep 1;14(17):5357-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
  • PURPOSE: To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression.
  • EXPERIMENTAL DESIGN: We did immunohistochemical analyses of CTSK and CXCL14 expression in normal breast tissue, biopsy sites, benign lesions, ductal carcinoma in situ, and invasive breast tumors of different stages.
  • Expression patterns were related to histopathologic characteristics of the tumors and clinical outcome.
  • RESULTS: Epithelial expression of CTSK was rarely detected in any of the tissue samples analyzed, whereas CXCL14-positive epithelial cells were found in all tissue types.
  • The expression of CXCL14 was not associated with any tumor or patient characteristics analyzed.
  • Stromal CTSK expression was significantly higher in invasive compared with in situ carcinomas, and in one of the two data sets analyzed, it correlated with higher tumor stage.
  • Neither epithelial nor stromal expression of CTSK was significantly associated with recurrence-free or overall survival.
  • Coculture of CTSK+ fibroblasts enhanced the invasion of CTSK- breast tumor epithelial cells and this was blocked by CTSK inhibitors.
  • CTSK+ fibroblasts may play a role in tumor progression by promoting the invasiveness of tumor epithelial cells.
  • The possibility that CTSK inhibitors may have a clinical role in decreasing the risk of tumor progression merits further investigation.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 2006 Aug;34(8):1101-5 [16863917.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):753-62 [14644202.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11550-3 [17158190.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(3):983-92 [17130243.001]
  • [Cites] Curr Pharm Des. 2007;13(4):387-403 [17311556.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7378-85 [17671208.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30794-803 [17724031.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9894-902 [17942921.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 28;364(4):1037-42 [17971304.001]
  • [Cites] Biochimie. 2008 Feb;90(2):380-6 [17991442.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5386-90 [9393764.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8 [9811821.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8262-70 [15548693.001]
  • [Cites] Biol Chem. 2004 Nov;385(11):1017-27 [15576321.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5490-8 [15843547.001]
  • [Cites] Prostate. 2005 Jun 15;64(1):67-74 [15651028.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1937-50 [10854217.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5697-702 [11479200.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):362-75 [12651909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 22;348(2):406-12 [16884687.001]
  • (PMID = 18765527.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116235-01A1; United States / NCI NIH HHS / CA / CA116235; United States / NCI NIH HHS / CA / CA116235-01A1; United States / NCI NIH HHS / CA / R01 CA094074-04; United States / NCI NIH HHS / CA / CA116235-02; United States / NCI NIH HHS / CA / R01 CA116235-02; United States / NCI NIH HHS / CA / CA089393-050004; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / CA089393-060014; United States / NCI NIH HHS / CA / P50 CA089393-060014; United States / NCI NIH HHS / CA / R01 CA116235; United States / NCI NIH HHS / CA / CA094074-05; United States / NCI NIH HHS / CA / CA094074-04; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA006516; United States / NCI NIH HHS / CA / P50 CA089393-050004; United States / NCI NIH HHS / CA / R01 CA094074-05; United States / NCI NIH HHS / CA / K08 CA090876; United States / NCI NIH HHS / CA / CA107469; United States / NCI NIH HHS / CA / CA89393; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA089393-070014; United States / NCI NIH HHS / CA / P50 CA089393-070014; United States / NCI NIH HHS / CA / R01 CA094074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL14 protein, human; 0 / Chemokines, CXC; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
  • [Other-IDs] NLM/ NIHMS72319; NLM/ PMC2630242
  •  go-up   go-down


10. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS: Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol; 2007 Apr;38(4):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Membranous immunoreactivity for each protein was semiquantitatively scored in both the tumor and adjacent benign epithelium in each case.
  • Variable membranous positivity was noted in the adjacent benign glands for all 5 proteins in all cases.
  • PACs showed variable membranous positivity ranging from decreased, similar to, and increased in relation to the adjacent benign epithelium for all claudins.
  • Decreased expression of claudin-1 correlated with high tumor grade (P = .001) and biochemical disease recurrence (P = .01), whereas decreased claudin-7 correlated with high tumor grade (P < .0001).
  • In contrast, expression of claudin-3 correlated with advanced stage tumors (P = .03) and recurrence (P = .02), and expression of claudin-4 correlated with advanced stage (P = .02).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306334.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


11. Conesa-Zamora P, Doménech-Peris A, Ortiz-Reina S, Orantes-Casado FJ, Acosta-Ortega J, García-Solano J, Pérez-Guillermo M: Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol; 2009 Feb;62(2):159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Considering the sparse information about the clinical utility of the novel immunohistochemical marker ProEx C in histological sections, a decision was taken to study the pattern of ProEx C expression in normal/benign cervical epithelium (N/B), low-grade squamous intraepithelial lesion (LGSIL) and high-grade squamous intraepithelial lesion (HGSIL), as well as the association of ProEx C expression with human papillomavirus (HPV) genotypes.
  • RESULTS: ProEx C-positive expression in more than the lower third of the epithelium was observed in 14.3% of N/B, 62.5% of LGSIL and 90.2% of HGSIL.
  • Seventy percent of HPV positivity was found in cases with expression in more than the lower third of the epithelium.
  • Of 31 cases that were positive for HPV16, 16.1% showed ProEx C expression restricted to one or two basal layers, and 83.9% showed ProEx C expression in more than the lower third of the epithelium.
  • CONCLUSIONS: ProEx C is significantly associated with HPV16 infection and is a useful adjunct in the identification of LGSIL and HGSIL in histological sections when expressed in more than the lower third of the epithelium.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cervix Uteri / metabolism. Female. Genotype. Human papillomavirus 16 / isolation & purification. Humans. Immunoenzyme Techniques / methods. Indicators and Reagents. Papillomaviridae / classification. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Precancerous Conditions / virology. Tissue Array Analysis


12. Garneau H, Paquin MC, Carrier JC, Rivard N: E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol; 2009 Nov;221(2):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Having previously demonstrated that E2F4 is cytoplasmic in quiescent-differentiated cells but nuclear in growth factor-stimulated proliferative cells, the present study was aimed at determining the role of E2F4 in the control of human intestinal epithelial proliferation.
  • Results herein demonstrate that lentiviral infection of an shRNA which specifically knocked-down E2F4 expression slowed down G1/S phase transition and the proliferation rate of normal human intestinal epithelial cells (HIEC) and of colon cancer cells.
  • Lastly, E2F4 and its target cyclin A were up-regulated and mostly nuclear in human colorectal tumor cells in comparison to the corresponding benign epithelium.
  • These results indicate that nuclear E2F4 may be determinant in the promotion of proliferation of human intestinal epithelial crypt cells and colorectal cancer cells.
  • [MeSH-minor] Agar. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Proliferation. Cyclin A / metabolism. DNA / biosynthesis. Down-Regulation. Epithelial Cells / cytology. Epithelial Cells / metabolism. G1 Phase. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Protein Transport. S Phase

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AGAR-AGAR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562678.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / E2F4 Transcription Factor; 0 / E2F4 protein, human; 9002-18-0 / Agar; 9007-49-2 / DNA
  •  go-up   go-down


13. Durdević S, Stojanović S, Marijana BN, Maksimović M: [Rational application of tumor marker CA 125 in gynecological oncology]. Med Pregl; 2010 Mar-Apr;63(3-4):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rational application of tumor marker CA 125 in gynecological oncology].
  • CA 125 antigen is produced in amniotic cells of the 7 week-old embryo, while in adults it can be detected in epithelium of most organs which originate from Müller ducts.
  • APPLICATION OF TUMOR MARKER CA 125 IN GYNECOLOGICAL ONCOLOGY: More than 83% of patients with epithelial ovarian carcinoma have elevated values of CA 125 higher than 35 U/mL at the moment of diagnosing the disease.
  • In cases of ovarian carcinoma, preoperatively determined values of CA 125 in serum are correlated with the extent of the expansion of the disease, histological type of tumor and degree of differentiation of malignant cells.
  • Elevated values up to 65 U/mL in sernum can also be found in other malignant minors (pancreas, breast, colon, bladder, lungs, liver) and in different benign diseases.
  • Postoperative levels of CA 125 >35 U/ mL in patients with no residual tumor and values >65 U/mL in those with residual tumor implants represent a separate prognostic factor in further course of the disease.
  • CONCLUSION: The importance of continuous determination of CA 125 tumor marker has to be adjusted to each single case.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Genital Neoplasms, Female / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053460.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


14. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ: Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep; 2007 Jul;18(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
  • In the ovary, this role is not clearly defined, with epithelial cancers being poorly responsive to hormone therapy.
  • To investigate the role of these receptors in ovarian carcinogenesis and their implications for cancer prognosis, we evaluated the immunohistochemical expression of ER, progesterone receptor (PR) and COUP-TFI in benign and malignant ovarian epithelial neoplasms and in normal ovaries.
  • A total of 113 ovarian specimens, including 40 diagnosed as malignant epithelial neoplasms (group A), 45 as benign epithelial tumors (group B), and 28 from normal ovaries (group C) were analyzed.
  • Multivariate analysis revealed a residual tumor <1 cm as the most significant clinical prognostic factor in group A (p=0.010, OR=4.14).
  • [MeSH-major] COUP Transcription Factor I / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549341.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / COUP Transcription Factor I; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


16. Fujita S, Seki S, Fujiwara M, Ikeda T: Midkine expression correlating with growth activity and tooth morphogenesis in odontogenic tumors. Hum Pathol; 2008 May;39(5):694-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midkine expression correlating with growth activity and tooth morphogenesis in odontogenic tumors.
  • MK plays a role in morphogenesis of many organs including teeth through epithelial-mesenchymal interactions.
  • We immunohistochemically examined MK expression in various human odontogenic tumors.
  • There was no difference in positive rate and intensity of MK between benign odontogenic tumors and their malignant counterparts.
  • MK was also preferentially expressed in keratinized cells in acanthomatous ameloblastoma and keratocystic odontogenic tumor.
  • In odontogenic mixed tumors except for odontoma, intense immunoreactivity to MK was found in epithelial follicles, the surrounding odontogenic ectomesenchymal tissue, and the basement membrane between them.
  • Intensity in the odontogenic ectomesenchyme decreased in relation to distance from the epithelial follicles.
  • No expression was found in tumor cells associated with production of dental hard tissues in odontogenic mixed tumors including odontoma.
  • These findings suggested that MK is involved in the reciprocal interaction between odontogenic epithelium and odontogenic ectomesenchymal tissue in areas without dental hard tissue formation in odontogenic mixed tumors.
  • Coexpression of MK and proliferating cell nuclear antigen was also observed in epithelial follicles and highly cellular nodules in the ectomesenchyme of odontogenic mixed tumors.
  • MK is considered to mediate growth activity of odontogenic tumors and cell differentiation of odontogenic mixed tumors through molecular mechanisms similar to those involved in morphogenesis of the tooth.
  • [MeSH-major] Nerve Growth Factors / biosynthesis. Odontogenesis / physiology. Odontogenic Tumors / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329695.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MDK protein, human; 0 / Nerve Growth Factors
  •  go-up   go-down


17. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS: Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int; 2006 Aug;98(2):445-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH) and normal prostate epithelium were represented on the array.
  • CONCLUSIONS: FEN-1 is overexpressed in prostate cancer compared with matched normal prostate, and its expression increases with tumour dedifferentiation, as shown by increasing Gleason score.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Flap Endonucleases / metabolism. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Cohort Studies. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood


18. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • It is usually benign and located in the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • Microscopic examination revealed that the wall of the cystic mass consists of a lining epithelium composed of columnar and squamous epithelium and a stroma composed of fibrous tissue containing scattered discontinuous bundles of smooth muscle fibers.
  • [MeSH-major] Cysts / diagnosis. Hamartoma / diagnosis. Peritoneal Neoplasms / diagnosis. Rectal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Stamatiou K, Polizois K, Kollaitis G, Dahanis S, Zafeiropoulos G, Leventis C, Lambou T: Cystic nephroma: a case report and review of the literature. Cases J; 2008;1(1):267
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The spectrum of cystic renal neoplasms includes both benign and malignant tumors and the order is as follows: benign multilocular cyst, multilocular cystic renal cell cancer and cystic renal cell cancer.
  • Gross similarities among multicystic tumors of the kidney may cause conflict in the diagnosis and treatment of these lesions.
  • Immuno-histological staining of the epithelium of the tumour with CK 19 suggested an aberrant renal tubular differentiation.
  • CONCLUSION: Cystic nephroma is a relatively rare benign lesion of the kidney.
  • Since 1892, only 200 cases have been reported in the international literature.
  • Final diagnosis can be established in the histopathological examination of the completely rejected tumor in the pathology laboratory.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Urology. 1991 Feb;37(2):156-62 [1846992.001]
  • [Cites] J Urol. 1987 Aug;138(2):397-9 [3037125.001]
  • [Cites] Radiology. 1983 Feb;146(2):309-21 [6294736.001]
  • [Cites] J Pediatr Surg. 1977 Oct;12(5):749-50 [915674.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] J Pediatr. 1959 Apr;54(4):429-45 [13642217.001]
  • [Cites] Int J Surg Pathol. 2009 Apr;17(2):170-1 [18611925.001]
  • [Cites] J Korean Med Sci. 2007 Feb;22(1):159-62 [17297273.001]
  • [Cites] Int Braz J Urol. 2006 Mar-Apr;32(2):187-9; discussion 189 [16650296.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):26-56 [16462154.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):217-22 [16393684.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1404-11 [15578885.001]
  • [Cites] J Urol. 2000 Jun;163(6):1860 [10799201.001]
  • (PMID = 18947428.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Kilic N, Tilki D, Ergün B, Seitz M, Stief CG, Reich O, Ergün S: Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor. Anticancer Res; 2010 Jul;30(7):2651-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
  • BACKGROUND/AIM: To study the expression of the pro-angiogenic factor carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in epididymal adeno-matoid tumor tissue, a very rare benign neoplasia, in relation to its vascularization.
  • MATERIALS AND METHODS: Immunohistochemistry for CEACAM1 and for both endothelial markers CD31 and CD34 was performed in normal human epididymal and epididymal adenomatoid tumor tissue.
  • The vessel density was calculated in four tumor regions with different degrees of vascularization in comparison to the vascularization of the normal epididymal tissue.
  • RESULTS: CEACAM1 was found in normal epididymal epithelium, while the epithelium of tumor glands was mostly negative.
  • Only few blood vessels and lymphatics in adenomatoid tumor tissue expressed CEACAM1.
  • The assessment of vascularization revealed either equal or a significantly lower vessel density in some adenomatoid tumor regions in comparison to normal epididymal tissue.
  • DISCUSSION: These data demonstrate that despite its epithelial down-regulation, CEACAM1 is not present in the majority of adenomatoid tumor blood vessels, which might be related to the lower angiogenic activity and benign behaviour of this tumor.
  • [MeSH-major] Adenomatoid Tumor / blood supply. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Testicular Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Endothelial Cells / metabolism. Epididymis / blood supply. Epididymis / metabolism. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682994.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


21. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Clinicopathologically, it has been suggested that clear cell tumors develop from endometriosis, but there has been little molecular evidence supporting this speculation.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Among 30 clear cell tumors, 17 (56%) cases were associated with endometriosis, and endometriotic epithelium was identified in 12 cases.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


22. Shahmahmoudi S, Mahmoodi M, Azad TM, Rad KS, Tabatabaie H, Sarijlou M, Pour YY, Yousefi M, Ghasemi M, Far KJ, Nategh R: Prevalence of mucosal types of human papillomavirus in skin lesions in north part of Iran. Cancer Lett; 2007 Mar 8;247(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses (HPVs) consist of more than 100 types and are known to be associated with numerous malignant tumors, including carcinomas of the mucosal and cutaneous epithelium.
  • Some studies have shown that NMSC biopsy specimens harbor cutaneous as well as mucosal human papillomavirus, suggesting that mucosal types may play a role in development and progression of the tumor in skin.
  • To investigate the presence of mucosal HPV types in skin lesions, we performed a retrospective study in which 288 paraffin embedded biopsies from benign and malignant skin lesions (NMSC) were collected.
  • Using nested PCR with MY09/11 and GP5+/6+ primers mucosal HPVs were detected in 25.7% of malignant specimens, but just in 0.7% of benign lesions.
  • [MeSH-major] Papillomaviridae / isolation & purification. Skin Diseases / virology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644111.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


23. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen AM, Komulainen M, Kosma VM, Anttila M: Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer; 2009;9:143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in malignant epithelial ovarian tumors, and associates with an unfavorable prognosis.
  • METHODS: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups: malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase activity, hyaluronan staining, and HAS1-3 immunoreactivity in tissue sections of the same specimens.
  • CONCLUSION: The results indicate that in serous epithelial ovarian malignancies HAS expression is not consistently elevated but HYAL1 expression is significantly reduced and correlates with the accumulation of hyaluronan. (233 words).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Mar;174(3):1027-36 [19218337.001]
  • [Cites] Matrix Biol. 2008 Oct;27(8):653-60 [18762256.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3361-70 [11058590.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):35111-22 [11451952.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):499-508 [11731267.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):509-14 [11731268.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4593-6 [11717318.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):212-9 [12397638.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6410-3 [12438225.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):359-64 [14506734.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5318-24 [14614016.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):247-52 [14750176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7832-7 [8755562.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):13997-4000 [9206724.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):327-31 [9359477.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):987-1003 [9714186.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):207-12 [15386412.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1681-9 [15870886.001]
  • [Cites] Pathol Biol (Paris). 2005 Sep;53(7):372-82 [16085113.001]
  • [Cites] Arkh Patol. 2005;Suppl:1-64 [16108150.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7782-9 [16140946.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):483-91 [18199543.001]
  • [Cites] Glycobiology. 2008 Apr;18(4):280-9 [18234732.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):150-5 [10646867.001]
  • (PMID = 19435493.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.212 / hyaluronan synthase; EC 3.2.1.35 / Hyaluronoglucosaminidase
  • [Other-IDs] NLM/ PMC2689240
  •  go-up   go-down


24. Kitada M, Ozawa K, Sato K, Matsuda Y, Hayashi S, Sasajima T: Resection of a mediastinal mature teratoma diagnosed owing to sudden chest pain with elevated preoperative serum CA19-9. Gen Thorac Cardiovasc Surg; 2010 Jun;58(6):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mediastinal teratomas are typically benign and asymptomatic, but they undergo sudden enlargement or rupture into neighboring organs in some patients owing to intratumoral hemorrhage, leading to serious complications.
  • Chest radiography and computed tomography revealed a mediastinal tumor and a serum CA19-9 level that was elevated to 4377 U/ml.
  • The tumor comprised soft tissue, fluid, and cystic components.
  • Most epithelial components, including squamous epithelium and similar components in the bronchi, showed positive results for CA19-9 on immunohistological examination.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Chest Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2006 Mar;54(3):117-9 [16613230.001]
  • [Cites] J Clin Lab Anal. 2007;21(2):103-6 [17385665.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 1999 Jun;37(6):509-13 [10434554.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2002 Sep;50(9):398-412 [12387248.001]
  • [Cites] Kyobu Geka. 2004 Jul;57(8 Suppl):784-8 [15362560.001]
  • [Cites] Kyobu Geka. 2003 Mar;56(3):247-50 [12649920.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):323-8 [9456938.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1994 Nov;42(11):2139-43 [7836831.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Dec;34(12):1359-63 [9022320.001]
  • [Cites] Kyobu Geka. 2000 Feb;53(2):158-61 [10667030.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2002 Jan;40(1):50-4 [11925919.001]
  • [Cites] Surg Gynecol Obstet. 1947 Oct;85(4):467-91 [20264332.001]
  • (PMID = 20549462.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


25. Riddle ND, Quigley BC, Browarsky I, Bui MM: Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature. Case Rep Med; 2010;2010:252364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Context. Leiomyosarcomas are rare malignant smooth muscle tumors that may arise in any organ or tissue that contains smooth muscle, commonly within the gastrointestinal tract.
  • The tumor clearly originated from the pancreatic duct wall, filled and expanded the duct lumen, and was covered with a layer of benign biliary epithelium.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tunis Med. 2005 May;83(5):288-91 [16044903.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Curr Surg. 2004 Nov-Dec;61(6):572-5 [15590026.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):548-51 [15661250.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):22-6 [15885579.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1226-9 [16343220.001]
  • [Cites] Urology. 2006 Feb;67(2):424.e13-424.e15 [16461113.001]
  • [Cites] J Foot Ankle Surg. 2006 Mar-Apr;45(2):127-30 [16513508.001]
  • [Cites] No Shinkei Geka. 2006 Apr;34(4):409-13 [16613223.001]
  • [Cites] Int Surg. 2005 Nov-Dec;90(5):262-5 [16625943.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):137-41 [16330234.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):466-70 [16872443.001]
  • [Cites] Actas Urol Esp. 2006 Jun;30(6):638-40 [16921844.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Oct;263(10):929-34 [16804717.001]
  • [Cites] Arch Esp Urol. 2006 Sep;59(7):728-31 [17078398.001]
  • [Cites] Arch Esp Urol. 2006 Nov;59(9):908-10 [17190216.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):628-33 [17451590.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):634-7 [17451591.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):963-77 [17574946.001]
  • [Cites] Obstet Gynecol Surv. 2007 Jul;62(7):480-6 [17572920.001]
  • [Cites] World J Gastroenterol. 2008 May 14;14(18):2942-5 [18473429.001]
  • [Cites] Pancreas. 2008 Aug;37(2):230-1 [18665093.001]
  • [Cites] Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):158-61 [18720751.001]
  • [Cites] Korean J Radiol. 2007 Nov-Dec;8(6):541-4 [18071285.001]
  • [Cites] HPB (Oxford). 2002;4(3):145-8 [18332943.001]
  • [Cites] Radiat Med. 1999 May-Jun;17(3):239-41 [10440114.001]
  • [Cites] Abdom Imaging. 1999 May-Jun;24(3):299-300 [10227898.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2352-8 [10357405.001]
  • [Cites] Clin Lab Haematol. 1999 Jun;21(3):219-24 [10448606.001]
  • [Cites] Int J Pancreatol. 1999 Dec;26(3):193-9 [10732297.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):189-92 [15221604.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Apr;96(4):286-7 [15259151.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):433-4 [15332041.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):690-2 [16053897.001]
  • (PMID = 20589089.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892659
  •  go-up   go-down


26. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • The epithelium demonstrated positive nuclear immunoreactivity for WT1 and PAX8, and was devoid of myoepithelium or basement membrane.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


27. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR: The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med; 2008 Apr;132(4):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
  • CONTEXT: The differentiation of benign mesothelial proliferations from malignant mesotheliomas may be difficult, especially when evaluating small specimens from pleural biopsies.
  • OBJECTIVE: To explore the potential value of 2 proliferative cell markers, Ki-67 and restrictedly expressed proliferation-associated protein 86 kDa (repp86), in distinguishing between malignant mesothelioma (MM) and benign reactive mesothelial hyperplasia (MH).
  • DESIGN: Thirty-six cases of MM from 26 men and 10 women with a mean age of 62.9 years (range, 36-80 years) and 22 cases of benign reactive MH from 14 male and 8 female patients with a mean age of 51.5 years (range, 15- 88 years) were included in this study.
  • RESULTS: The mean labeling indexes for Ki-67 in MM and benign reactive MH were 24.6% (range, 1%-66%) and 6.23% (range, 0%-25%), respectively.
  • The mean labeling indexes for repp86 in MM and benign reactive MH were 26.3% (range, 0%-50%) and 3.26% (range, 0%- 21%), respectively.
  • The average proliferative cell count was significantly higher in MM compared with benign reactive MH (P < .001).
  • Furthermore, both markers showed a significant correlation in their expression in MM and benign reactive MH (r = 77.5, P < .001).
  • CONCLUSIONS: Used in combination, Ki-67 and repp86 appear to be useful markers in differentiating MM from benign reactive MH.
  • [MeSH-major] Epithelium / metabolism. Ki-67 Antigen / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Neoplasms, Mesothelial / diagnosis. Neoplasms, Mesothelial / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Hyperplasia / pathology. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384222.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / SND1 protein, human
  •  go-up   go-down


28. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol; 2008 May;109(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Identifying markers specific for mucinous ovarian neoplasms (MON) is important for cancer diagnosis and surveillance, and will help improve our general understanding of the pathobiology of these tumors.
  • METHODS: Western blot compared CEACAM6 expression in normal human ovarian surface epithelium (HOSE) and ovarian cancer cell lines.
  • 100-fold CEACAM6 overexpression (qRT-PCR) was demonstrated in 13/16 (81%) borderline, low-grade, and high-grade invasive MON's, compared to 5/50 (10%) serous and 1/5 (20%) benign mucinous samples.
  • CEACAM6 expression was not different between borderline and invasive MON's (p=0.55) or across tumor stage (p=0.76).
  • None of the serous or benign mucinous tumors exhibited CEACAM6 staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / metabolism. Epithelium / metabolism. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Ovary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Staining and Labeling. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331757.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  •  go-up   go-down


29. Oxenius I, Vacirca F: [A rare case of fibroepithelial polyp of the proximal urethra in a young woman]. Urologia; 2008 Jul-Sep;75(3):193-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroepithelial polyps are benign epithelial tumours which are rare in adults.
  • We report a case of a twenty-seven-year-old woman, presenting with painless terminal gross haematuria, affected by a neoplasm located in the proximal urethra near the bladder neck.
  • Endoscopic image of the tumour and histopatological details are shown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086351.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dall'Era MA, Oudes A, Martin DB, Liu AY: HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate; 2007 May 15;67(7):714-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD10 is strongly expressed by normal prostate epithelium.
  • While only 30% of primary prostate tumors express CD10, it is strongly expressed by most lymph node metastases.
  • In this study, we compared CD10 mRNA and protein expression between benign and malignant prostate cells and employed proteomic analysis to identify proteins that interact with CD10 in C4-2 prostate cancer cells.
  • [MeSH-major] HSP70 Heat-Shock Proteins / metabolism. Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Neprilysin / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Membrane / metabolism. Drug Interactions. Gene Expression Regulation, Neoplastic. HSP27 Heat-Shock Proteins. Humans. Male. Proteomics. RNA, Messenger / genetics. RNA, Messenger / metabolism


31. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


32. Zhen B, Shen Y, Zhang YM, Zhu CH, Liu ZL: [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues]. Zhonghua Nan Ke Xue; 2006 May;12(5):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
  • OBJECTIVE: To examine the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia (BPH) and prostatic cancer (PCa) tissues and to analyse the relationship between their expression and BPH and PCa, especially the relationship with the occurrence, development, prognosis and treatment of PCa.
  • The glandular epithelium stained very strongly positively and the stroma stained positively.
  • The staining for c-kit in BPH tissues was located in the cytoplasm of smooth muscle cells, and in PCa tissues was located in epithelial cells.
  • CONCLUSION: The expression level of HSP27 and c-kit was highly correlated with the process of the development from BPH to PCa, and also correlated with tumor grades and stages.
  • [MeSH-major] Heat-Shock Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis


33. Cho JM, Ahn JY, Kim SH, Lee KS, Chang JH: An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata. Childs Nerv Syst; 2010 Jun;26(6):853-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata.
  • INTRODUCTION: Endodermal cysts, also known as enterogenous, neurenteric, foregut, epithelial, bronchogenic, or respiratory cysts, are rare benign lesions lined by columnar epithelium of a presumed endodermal origin.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis. Medulla Oblongata

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2011 Jun;27(6):861-2; author reply 863 [21503756.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):401-4; discussion 404-5 [9932896.001]
  • [Cites] AMA Am J Dis Child. 1952 Apr;83(4):500-7 [14902104.001]
  • [Cites] Australas Radiol. 2006 Feb;50(1):59-62 [16499730.001]
  • [Cites] Surg Gynecol Obstet. 1954 Aug;99(2):135-41 [13187191.001]
  • [Cites] Can J Neurol Sci. 1989 May;16(2):206-10 [2731091.001]
  • [Cites] J Neurosurg Spine. 2005 Mar;2(3):372-6 [15796365.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1091-3 [15200128.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):583-7; discussion 587-8 [2034355.001]
  • [Cites] AMA Arch Pathol. 1952 Aug;54(2):132-8 [14943345.001]
  • [Cites] Childs Nerv Syst. 1988 Feb;4(1):47-9 [3401868.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):243-5; discussion 246 [12493126.001]
  • [Cites] Clin Radiol. 1985 May;36(3):245-51 [4064506.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1211-6 [16775266.001]
  • [Cites] J Neurosurg. 1998 Aug;89(2):326-35 [9688132.001]
  • [Cites] Arq Neuropsiquiatr. 1993 Jun;51(2):253-7 [8274091.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):764-7 [10981766.001]
  • [Cites] Pediatr Clin North Am. 1958 May;:457-74 [13542070.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):229-53 [1476931.001]
  • [Cites] Br J Surg. 1954 Mar;41(169):520-33 [13149822.001]
  • [Cites] Neurol Med Chir (Tokyo). 2008 Feb;48(2):86-9 [18296879.001]
  • (PMID = 20217097.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Mocanu L, Cîmpean AM, Raica M: Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions. Rom J Morphol Embryol; 2006;47(4):351-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleural effusions occur in many benign and malignant conditions.
  • The differentiation of mesothelial hyperplasia, malignant epithelial mesothelioma and metastatic adenocarcinoma in cytologic specimens is often difficult.
  • In this study, immunostaining was performed on 30 smears from seven patients with inflammatory pleural effusions, 21 patients with metastatic pleural effusions and two patients with malignant epithelial mesothelioma.
  • Benign mesothelial cells expressed HBME-1 in 13 (46.43%) cases with thick and thin membrane pattern and with thin membrane and cytoplasmic pattern in 11 (39.29%) cases.
  • Metastatic tumor cells were positive for HBME-1 in seven (33.33%) cases; the staining pattern in metastatic adenocarcinoma cells was thin membrane and focal cytoplasmic.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Epithelium / pathology. Humans. Inflammation

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392981.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen
  •  go-up   go-down


35. Shi YC, Tang LF, Chen ZM, Du LZ: Pleuropulmonary blastoma in an infant. Indian J Pediatr; 2009 Sep;76(9):948-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleuropulmonary blastomas (PPB) are rare and highly aggressive tumors.
  • The immature blastematous tissue was positive for vimentin while benign epithelium was positive for epithelial membrane antigen and cytokeratin.
  • No lymph nodule metastasis was found in the 7 lymph nodules obtained from the hilum of the lung near the tumor.


36. Hotakainen K, Bjartell A, Sankila A, Järvinen R, Paju A, Rintala E, Haglund C, Stenman UH: Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol; 2006 Jan;28(1):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
  • Tumor-associated trypsin inhibitor (TATI) is a marker of mucinous ovarian carcinoma, but it is also widely expressed in other malignant tumors and normal human tissues.
  • Tumor-associated trypsin is co-expressed with TATI in many malignancies and is thought to be involved in tumor invasion.
  • We therefore studied whether trypsinogen expression also can be detected in bladder cancer and how this and TATI expression are associated with the clinicopathological characteristics of the tumors.
  • We used RT-PCR, in situ hybridization and immunohistochemistry to detect trypsinogen- and TATI mRNA and protein in tissue samples from 28 bladder cancer patients and ten benign urothelia.
  • TATI expression was detected in all benign tissues and non-invasive tumors.
  • However, the expression was lower in the muscle-invasive tumors (pT2; n=5), whereas trypsinogen expression was seen in all but one non-invasive tumor.
  • We conclude that trypsinogen is expressed in both malignant and benign bladder epithelium, whereas TATI expression decreases with increasing stage and grade of the tumor.
  • This may suggest that a balanced expression of TATI and trypsinogen is required in normal tissue and that this balance is disrupted during tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Disease Progression. Epithelium. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327984.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic; 9002-08-8 / Trypsinogen
  •  go-up   go-down


37. Hoory T, Monie A, Gravitt P, Wu TC: Molecular epidemiology of human papillomavirus. J Formos Med Assoc; 2008 Mar;107(3):198-217
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These small, non-enveloped, double-stranded DNA viruses primarily infect the epithelium and induce benign as well as malignant lesions of the mucosa and skin.
  • Some HPVs are considered to be high-risk due to their strong implication in carcinogenesis, particularly the malignant progression of cervical tumors.
  • The recognition of papillomaviruses as a major etiologic agent for human cancers has increased their medical importance and stimulated research into developing strategies for the screening, diagnosis, prevention and treatment of HPV-associated diseases.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18400605.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA114425-01; United States / NCI NIH HHS / CA / 1R01 CA118790; United States / NCI NIH HHS / CA / P50 CA098252
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Singapore
  • [Number-of-references] 164
  •  go-up   go-down


38. Heye S, Bielen D, Vanbeckevoort D: Left ovarian Brenner tumor. JBR-BTR; 2005 Sep-Oct;88(5):245-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ovarian Brenner tumor.
  • Ovarian Brenner tumors are uncommon neoplasms of the ovary, representing approximately 2% of all ovarian neoplasms.
  • Nowadays there is general agreement that Brenner tumors are derived from the surface epithelium of the ovary or the pelvic mesothelium through transitional cell metaplasia.
  • We report a case of benign ovarian Brenner tumor and discuss the typical features on magnetic resonance imaging (MRI) and computed tomography (CT) scan as well as the differential diagnosis.
  • [MeSH-major] Brenner Tumor / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302335.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


39. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • In addition to benign endocervical epithelium, 19 of these 23 control cases also showed focal tubal metaplasia.
  • Fourteen of 19 (74%) tubal metaplasia cases showed p16(INK4a) immunoreactivity in >50% of the tubal metaplastic epithelium with staining intensity ranging from weak to strong.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism


40. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW: Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate; 2005 Jun 1;63(4):369-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
  • BACKGROUND: We have sought to develop a new in vivo model of prostate carcinogenesis using human prostatic epithelial cell cultures.
  • METHODS: We took advantage of the ability of retroviruses to integrate foreign DNA into human prostatic epithelium (huPrE) to generate cell lines that overexpress the c-MYC protooncogene.
  • The tumors were rapidly growing with a high proliferative index.
  • The neoplastic cells in the tumor expressed both androgen receptors (AR) and prostate-specific antigen (PSA), both characteristic markers of human prostate cancers.
  • Microarray analysis of human prostatic epithelial cells overexpression c-MYC identified a large number of differentially expressed genes some of which have been suggested to characterize a subset of human cancers that have myc overexpression.
  • Control grafts using either uninfected huPrE or using huPrE cells infected using an empty vector expressing a green fluorescent protein tag gave rise to well differentiated benign prostatic glandular ducts.
  • [MeSH-minor] Animals. Biomarkers, Tumor. Cells, Cultured. Disease Models, Animal. Epithelium / physiology. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Green Fluorescent Proteins / genetics. Humans. Male. Mice. Mice, SCID. Oligonucleotide Array Sequence Analysis. Phenotype. Retroviridae / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15937962.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA96403; United States / NCI NIH HHS / CA / P30 CA68485; United States / NIDDK NIH HHS / DK / P60 DK20593
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-myc; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


41. Picken MM, Fresco R: Mixed epithelial and stromal tumor of the kidney: preliminary immunohistochemical and electron microscopic studies of the epithelial component. Ultrastruct Pathol; 2005 May-Aug;29(3-4):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney: preliminary immunohistochemical and electron microscopic studies of the epithelial component.
  • Mixed epithelial and stromal tumor of the kidney is a rare biphasic tumor composed of cysts and tubules embedded in the spindle cell stroma.
  • Although the histogenesis of this tumor is unknown, it has been proposed that both components of the tumor, i.e., stromal and epithelial, are neoplastic.
  • The authors report preliminary immunohistochemical and electron microscopic studies of the epithelial component from one case of a typical, benign, mixed epithelial, and stromal tumor of the kidney.
  • By electron microscopy, some tubules had features of proximal tubular epithelium, while other tubules had features of the loop of Henle (thin segments).
  • The authors believe that in a benign tumor such morphologic heterogeneity is inconsistent with neoplastic proliferation.
  • Therefore, they postulate that in mixed epithelial and stromal tumor of the kidney the tubules are entrapped rather than neoplastic.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036882.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


42. Vucić M, Cupić H, Tomić K, Kruslin B: An unusual pattern of pseudoepitheliomatous hyperplasia associated with cutaneous primary melanoma: report of two cases with analysis of p53 and bcl-2 immunoreactivity. Acta Dermatovenerol Croat; 2007;15(2):72-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudoepitheliomatous hyperplasia (PEH) is a benign, reactive epithelial proliferation.
  • PEH is characterized by hyperplasia of the epidermis or adnexal epithelium into irregular squamous strands that extend deep down into the subjacent dermis.
  • [MeSH-major] Melanoma / metabolism. Melanoma / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631784.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


43. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.
  • Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


44. Diallo M, Cribier B, Scrivener Y: [Warty dyskeratoma: infundibular histogenesis. Anatomoclinical study of 43 cases]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The exact origin and classification of warty dyskeratoma in epithelial tumours are still debated.
  • The purpose of this study was to examine the relationship between this tumour and the pilosebaceous follicles.
  • DISCUSSION: Based on the histological and immunohistochemical findings, we proposed the hypothesis of benign epithelial tumour of follicular type, beginning in the pilar infundibulum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Child. Darier Disease / pathology. Epithelium / pathology. Hair Follicle / pathology. Histiocytes / pathology. Humans. Keratin-1 / analysis. Keratin-10 / analysis. Keratin-17 / analysis. Keratin-19 / analysis. Keratin-5 / analysis. Keratoacanthoma / pathology. Lymphocytes / pathology. Middle Aged. Retrospective Studies. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925685.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de venereologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Keratin-1; 0 / Keratin-17; 0 / Keratin-19; 0 / Keratin-5; 147785-83-9 / Keratin-10
  •  go-up   go-down


45. Duchi S, Fagnocchi L, Cavaliere V, Hsouna A, Gargiulo G, Hsu T: Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development; 2010 May;137(9):1493-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability.
  • Mutations in the human von Hippel-Lindau (VHL) genes are the cause of VHL disease, which displays multiple benign and malignant tumors.
  • Using an established follicular epithelial model in Drosophila, we show that the Drosophila VHL gene is involved in epithelial morphogenesis via stabilizing microtubule bundles and aPKC.
  • Microtubule defects in VHL mutants lead to mislocalization of aPKC and subsequent loss of epithelial integrity.
  • Destabilizing microtubules in ex vivo culture of wild-type egg chambers can also result in aPKC mislocalization and epithelial defects.
  • The results establish a developmental function of the VHL gene that is relevant to its tumor-suppressor activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1993 Apr;117(4):1223-37 [8404527.001]
  • [Cites] Development. 2008 Feb;135(3):463-71 [18094021.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):352-60 [7958405.001]
  • [Cites] Cell. 1995 Jul 14;82(1):67-76 [7606787.001]
  • [Cites] Development. 1997 Oct;124(19):3871-80 [9367443.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):959-68 [9651579.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):139-46 [15530850.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8688-94 [15467749.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):276-82 [15694314.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Mar;6(3):233-47 [15738988.001]
  • [Cites] Biochem J. 2006 Jan 15;393(Pt 2):471-80 [16176182.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1553-60 [16452212.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):979-87 [16525119.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):12069-80 [16505488.001]
  • [Cites] J Am Soc Nephrol. 2006 Jul;17(7):1801-6 [16775032.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6903-7 [16849532.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2054-6 [16969113.001]
  • [Cites] J Cell Sci. 2006 Oct 15;119(Pt 20):4155-63 [17038542.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):547-54 [17101696.001]
  • [Cites] Dev Cell. 2007 May;12(5):727-38 [17488624.001]
  • [Cites] FEBS Lett. 2007 Oct 2;581(24):4571-6 [17825299.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):15-27 [17936701.001]
  • [Cites] Nat Protoc. 2007;2(10):2467-73 [17947988.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):685-90 [18006292.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):361-9 [18297059.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4649-57 [18559510.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1208-16 [18806787.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):1089-101 [19073886.001]
  • [Cites] Dev Biol. 2009 May 15;329(2):294-305 [19285057.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):994-1001 [19620968.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):544-7 [10591216.001]
  • [Cites] Oncogene. 2000 Jun 1;19(24):2803-11 [10851083.001]
  • [Cites] Science. 2000 Jun 16;288(5473):2013-8 [10856208.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):355-61 [11006129.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):891-904 [11076972.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2929-36 [12019174.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1568-81 [12080094.001]
  • [Cites] Bioessays. 2002 Aug;24(8):690-5 [12210528.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1955-9 [12471248.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):46-52 [12510193.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):53-8 [12510194.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):64-70 [12510195.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):734-43 [12725730.001]
  • [Cites] Traffic. 2004 Jan;5(1):1-9 [14675420.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):845-54 [15177032.001]
  • [Cites] J Cell Biol. 2004 Aug 16;166(4):549-57 [15302858.001]
  • [Cites] Cell. 1990 Jun 1;61(5):787-99 [2344615.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):73-8 [17912253.001]
  • [Cites] J Cell Sci. 1993 Aug;105 ( Pt 4):993-1000 [8227220.001]
  • (PMID = 20388653.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078582-100005; United States / NCI NIH HHS / CA / R01CA109860; United States / NCI NIH HHS / CA / R01 CA109860; United States / NCI NIH HHS / CA / P01 CA078582-100005; United States / NCI NIH HHS / CA / P01 CA078582; United States / NIGMS NIH HHS / GM / GM057843-08; United States / NIGMS NIH HHS / GM / R01 GM057843; United States / NIGMS NIH HHS / GM / R01 GM057843-08; United States / NCI NIH HHS / CA / R01 CA109860-06; United States / NCI NIH HHS / CA / P01CA78582; United States / NCI NIH HHS / CA / CA109860-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drosophila Proteins; EC 2.7.11.13 / Protein Kinase C-alpha; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC2853850
  •  go-up   go-down


46. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


47. Kim TJ, Rho SB, Choi YL, Choi CH, Lee JW, Bae DS, Ahn G, Lee JH, Kim BG: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol; 2006 Jul;37(7):906-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate TIMP-2 level in serous ovarian tumor tissues and to understand further the role of TIMP-2 protein in ovarian tumorigenesis.
  • The expression of TIMP-2 was assessed by immunohistochemistry in a total of 57 ovarian specimens, including 5 normal ovaries, 12 benign serous cystadenomas, 20 serous borderline tumors, and 20 serous carcinomas.
  • We found that TIMP-2 immunostaining was significantly more frequent in serous carcinomas, mainly in tumor epithelium, compared with cells of the other tissues studied.
  • These findings suggest that TIMP-2 may function to favor tumor growth in serous ovarian tumorigenesis.
  • Additional research is now needed to elucidate further the role of TIMP-2 in the biologic behavior of ovarian serous tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784992.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Depondt J, Shabana el-H, Walker F, Pibouin L, Lezot F, Berdal A: Nasal inverted papilloma expresses the muscle segment homeobox gene Msx2: possible prognostic implications. Hum Pathol; 2008 Mar;39(3):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal inverted papilloma is a rare benign tumor of epithelial origin with aggressive evolution, bone destruction, recurrence, and malignant transformation.
  • The protein expression level was directly and significantly associated with tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Homeodomain Proteins / biosynthesis. Nose Neoplasms / genetics. Nose Neoplasms / metabolism. Papilloma, Inverted / genetics. Papilloma, Inverted / metabolism
  • [MeSH-minor] Acid Phosphatase / metabolism. Adult. Aged. Female. Gene Expression. Genes, Homeobox / physiology. Humans. Immunohistochemistry. Isoenzymes / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. RANK Ligand / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187185.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / MSX2 protein; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


49. Thomas S, Muralidharan A, Shah GV: Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol; 2007 Dec;31(6):1425-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin (CT) and its receptor (CTR) are expressed only in basal epithelium of benign prostate and in whole epithelium of malignant prostates.
  • Also, CT and CTR mRNA levels in prostate cancers increase with an increase in tumor grade.
  • This treatment also led to a remarkable decrease in endothelial cell populations in the tumors and increase in apoptotic, PCNA-negative cell populations.
  • Tumors receiving CTR RNAi treatment displayed markedly lower levels of urokinase-type plasminogen activator, phospho-Akt and survivin, suggesting CTR activates uPA-uPAR axis and PI-3-kinase-Akt-survivin pathway.
  • These results suggest an important role for CT-CTR autocrine axis in the progression of localized prostate tumor to a metastatic phenotype, and offer a potential therapeutic option for invasive cancers.


50. Karim A, Fowler M, McLaren B, Cardenas R, Patwardhan R, Nanda A: Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature. Clin Neurol Neurosurg; 2006 Sep;108(6):586-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Choroid plexus papillomas (CPP) are histopathologically benign and rare central nervous system (CNS) neoplasms arising from the epithelium of the choroid plexus.
  • Pathology from the biopsy and both resections was benign CPP.
  • Concomitant CPPs may be secondary to mere coincidental tumor occurrence or to biologic seeding of cerebrospinal fluid (CSF) from a primary CPP despite otherwise benign histopathology.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963638.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 21
  •  go-up   go-down


51. Shah SS, Mazur MT: Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol; 2008 Oct;27(4):534-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When prominent, this morphological alteration yields a pattern of eosinophilic epithelial cells, often in pseudopapillary arrangements that can mimic cellular changes seen in metaplastic and atypical endometrium.
  • Our methodology involved a retrospective immunohistochemical study on endometrial biopsies with proliferation markers Ki-67 (MIB-1 antibody) and phosphohistone H3 Ser 28 (pHH3) in 15 cases of multifocal ESC associated with benign endometrium, 5 cases of atypical hyperplasia, and 7 cases of endometrial carcinoma.
  • In the endometrial cancers, the Ki-67 proliferative index was 10.6% for FIGO grade 1 tumors (n=3), 27.6% for grade 2 tumor (n=1), and 79.6% for serous carcinoma (n=3).
  • Furthermore, when there is a question of whether eosinophilic endometrial epithelium represents this change, a combination of Ki-67 and pHH3 immunostains can be helpful in distinguishing this entity from more significant processes including carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753967.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


52. Harvey AM, Grice B, Hamilton C, Truong LD, Ro JY, Ayala AG, Zhai QJ: Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch Pathol Lab Med; 2010 Jul;134(7):983-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Seminal vesicle invasion by prostatic carcinoma is directly associated with tumor staging; verification is challenging when the tumor demonstrates cribriform or papillary growth patterns or there are back-to-back small-gland proliferations.
  • P504S is overexpressed in prostatic carcinoma and high-grade prostatic intraepithelial neoplasia with cytoplasmic immunoreactivity. p63 has positive immunoreactivity in basal cell nuclei of benign prostatic glands.
  • Seminal vesicle epithelium from all 57 cases was negative for all 3 markers with distinct p63 nuclear staining of the basal cells.
  • Benign prostatic tissue was positive for PSA and PAP, as well as for p63, but negative for P504S.
  • CONCLUSIONS: The P504S/p63 one-color cocktail is a practical and cost-effective stain to differentiate prostatic carcinoma that involves the seminal vesicle from seminal vesicle epithelium.
  • It is superior to PSA or PAP when sections contain both seminal vesicle and benign glands because PSA and PAP cannot distinguish benign from malignant glands.
  • [MeSH-minor] Acid Phosphatase. Cost-Benefit Analysis. Humans. Immunohistochemistry / economics. Immunohistochemistry / standards. Male. Neoplasm Invasiveness. Neoplasm Staging. Prostate / chemistry. Prostatectomy. Staining and Labeling / economics. Staining and Labeling / standards

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586625.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


53. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


54. Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S: p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch; 2006 May;448(5):597-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was carried out to assess the correlations between p16INK4A expression as an early biomarker of the endocervical adenocarcinoma and HPV infection. p16INK4A expression and HPV typing were performed on 46 samples including 5 normal endocervix, 9 benign lesions of the endocervix, 25 endocervical adenocarcinomas, and 7 endometrioid adenocarcinomas of the uterine corpus.
  • All of the 25 endocervical adenocarcinomas overexpressed p16INK4A; the adjacent epithelium and the connective tissue were strictly negative.
  • No p16INK4A was detected in nine benign endocervical lesions and in five normal endocervix.
  • Our results suggest that p16INK4A is a putative molecular biomarker that consistently discriminates uterine cervix adenocarcinomas from benign lesions and from endometrioid adenocarcinomas of the uterine corpus.
  • [MeSH-major] Adenocarcinoma / virology. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Papillomavirus Infections / complications. Tumor Virus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Annu. 1973;8:301-28 [4583016.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):42-55 [11237522.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):503-11 [7859739.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Pathol Int. 1995 Jul;45(7):506-12 [7551011.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1585-94 [10928993.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):55-61 [10502426.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):317-21 [14961567.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):659-66 [2169191.001]
  • [Cites] Br J Cancer. 1997;75(10):1410-6 [9166931.001]
  • [Cites] J Virol. 2004 Oct;78(20):11172-86 [15452237.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Annu Rev Microbiol. 1994;48:427-47 [7826013.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):8-15 [11241260.001]
  • [Cites] Anticancer Res. 1991 Jan-Feb;11(1):123-7 [1850213.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):71-5 [9495362.001]
  • [Cites] Am J Clin Pathol. 1996 Jul;106(1):52-6 [8701932.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1035-8 [9781637.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):439-45 [10831356.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Virol. 1988 May;62(5):1659-66 [2833616.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Int J Gynecol Pathol. 2003 Oct;22(4):378-85 [14501820.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] J Virol Methods. 1991 Nov-Dec;35(2):143-57 [1667785.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Yonsei Med J. 2002 Dec;43(6):722-8 [12497655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):668-73 [15041997.001]
  • [Cites] Mol Cell Endocrinol. 1996 Jan 15;116(1):115-9 [8822272.001]
  • (PMID = 16496173.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


56. Gyulai-Gaál S, Takács D, Barabás J, Tarján I, Martonffy K, Szabó G, Suba Z: [Mixed odontogenic tumors in children and adolescents]. Fogorv Sz; 2007 Apr;100(2):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed odontogenic tumors in children and adolescents].
  • Mixed odontogenic tumors in the jaws of children and adolescents usually cause dentition anomalies.
  • In the present study mixed odontogenic tumor cases are presented in patients under 20 years of age.
  • Ameloblastic fibromas (AFs) are true, mixed, soft tissue neoplasms, deriving from the proliferation of both odontogenic epithelium and mesenchyma.
  • Ameloblastic fibroodontomas (AFOs) may be regarded as hamartomas, which exhibit epithelial, mesenchymal and abundant hard tissue components of the developing teeth.
  • Odontomas are calcifying benign hamartomas, and represent the most common type of odontogenic jaw tumors among patients less than 20y, having complex and compound variants.
  • Early diagnosis and treatment of mixed odontogenic jaw tumors in children may prevent the serious orthodontic complications and jaw deformations.
  • [MeSH-major] Jaw Neoplasms / diagnosis. Jaw Neoplasms / surgery. Odontogenic Tumors / diagnosis. Odontogenic Tumors / surgery. Tooth Eruption, Ectopic / etiology. Tooth, Impacted / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546897.001).
  • [ISSN] 0015-5314
  • [Journal-full-title] Fogorvosi szemle
  • [ISO-abbreviation] Fogorv Sz
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


57. Song SY, Noh JH, Lee SJ, Son HJ: Bronchogenic cyst of the stomach masquerading as benign stromal tumor. Pathol Int; 2005 Feb;55(2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchogenic cyst of the stomach masquerading as benign stromal tumor.
  • Microscopically, the gastric subserosa showed cystic structures lined by pseudostratified ciliated columnar epithelium, seromucinous gland, connective tissue and complete layers of smooth muscle bundles.
  • Neither cartilage nor gastrointestinal epithelium was identified.
  • [MeSH-major] Bronchogenic Cyst / pathology. Gastrointestinal Stromal Tumors / diagnosis. Stomach Diseases / pathology. Stomach Neoplasms / diagnosis


58. Fan SQ, Liang QC, Jiang Y: Thyroid teratoma in an 11-month-old infant. Int J Surg; 2008 Dec;6(6):462-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of congenital benign thyroid teratoma in an 11-month-old male infant who was found to have right thyroid gland mass since birth.
  • The tumor was 25 x 20 x 15 mm with whole thin capsule and could be easily dissected from the surrounding normal thyroid tissue at surgery.
  • Histologically, tumor had mature derivatives of the three primordial germ layers with a variety of benign and well-differentiated elements.
  • It was the most conspicuous feature that the tumor was composed mainly of the neurological tissue resembling brain tissue with glial cells and ependymal epithelium components.
  • There were a few anastomosing variably sized tubules and cysts lined by ependymal epithelial cells with papillary feature and retinal pigment epithelial cells.
  • In summary, benign teratoma of thyroid gland in an 11-month-old infant was morphologically and immunophenotypically identified.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059145.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Brun JL, Cortez A, Rouzier R, Callard P, Bazot M, Uzan S, Daraï E: Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. Am J Obstet Gynecol; 2008 Sep;199(3):244.e1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors.
  • OBJECTIVE: The objective of the study was to study factors influencing the use and accuracy of frozen section diagnosis (FSD) of ovarian tumors.
  • STUDY DESIGN: Surgery was performed in 414 patients with epithelial ovarian tumors between 2001 and 2006.
  • RESULTS: FSD was requested in 274 patients: 152 benign, 55 borderline, and 67 malignant tumors.
  • Age 50 years or older, tumor size 10 cm or greater, and preoperative evidence of malignancy were associated with FSD request.
  • The sensitivity and specificity of FSD for benign, borderline, and malignant tumors were 97% and 81%, 62% and 96%, and 88% and 99%, respectively.
  • The histologic type (mucinous), tumor size (less than 10 cm), the borderline component (less than 10%), and the pathologist's experience predicted misdiagnosis of borderline tumors.
  • Spread outside the ovary was the only significant predictor of accurate FSD of malignant tumors.
  • CONCLUSION: FSD is less accurate for borderline than benign and malignant ovarian tumors.
  • [MeSH-minor] Epithelium / pathology. Female. Humans. Intraoperative Period. Likelihood Functions. Middle Aged. Multivariate Analysis. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486086.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Wang J, Zhang RY: [Ectopic hamartomatous thymoma: a clinicopathological and immunohistochemical study of two cases]. Zhonghua Bing Li Xue Za Zhi; 2005 Jul;34(7):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each patient presented with a solitary mass, one located in the suprasternal fossa and the other in the left supraclavicular region for a period of 6 months and 2 months respectively.
  • Histologically, both tumors were composed of a mixture of spindle cells, epithelial cells and mature adipose tissue.
  • Epithelial cells element represented nearly 10% in both cases.
  • Most of the epithelial cells had a non-keratinization squamous appearance.
  • A transition between the spindle cell and epithelium components could be also identified in some areas.
  • Mature adipose tissue was irregularly distributed in the two tumors, about < 5% and 20% respectively.
  • Immunohistochemically, the epithelial element expressed AE1/AE3, CK5, CK7, CK8 and EMA, whereas the spindle component expressed AE1/AE3, CK5, CK7, CK8, vimentin, CD10, CD34, alpha-SMA, MSA, and calponin.
  • CONCLUSIONS: EHT is a benign tumor that occurs predominantly in the lower neck region of young to middle-aged males.
  • Immunohistochemical study revealed myoepithelial differentiation of the spindle cells, suggesting EHT is a mixed tumor composed of epithelial and myoepithelial cells.
  • EHT possibly originates from the remnants of cervical sinus of His, and therefore, may be renamed as branchial anlage mixed tumor.
  • [MeSH-major] Choristoma / pathology. Hamartoma. Lymphatic Diseases / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251042.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Keratins, Type II; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


61. Klopfleisch R, Schütze M, Gruber AD: Loss of p27 expression in canine mammary tumors and their metastases. Res Vet Sci; 2010 Apr;88(2):300-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of p27 expression in canine mammary tumors and their metastases.
  • Here, p27 expression was analyzed on the protein level in non-neoplastic mammary gland, primary mammary carcinomas, their lymph node metastases and intravascular tumor cells of 49 dogs, adenomas of 49 dogs and non-neoplastic mammary gland of 98 dogs by immunohistochemistry.
  • Specifically, 91% of normal gland epithelium displayed nuclear p27 expression.
  • In contrast, only 22% of the adenomas, 20% of carcinomas, 12% of lymph node metastases and 32% of intravascular tumor cells had p27 reactivity.
  • Cell cycle control by p27 is therefore lost in the majority of canine mammary tumors.
  • The lack of significant differences between benign and malignant mammary tumors indicates that decreased p27 expression is an early step in carcinogenesis of canine mammary tumors and hinders the use of p27 as a marker of malignancy for this tumor type.
  • [MeSH-major] Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Proliferating Cell Nuclear Antigen / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19748645.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen
  •  go-up   go-down


62. Cheah PL, Looi LM: Significance of Bcl-2 and Bax proteins in cervical carcinogenesis: an immunohistochemical study in squamous cell carcinoma and squamous intraepithelial lesions. Malays J Pathol; 2006 Jun;28(1):1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen low grade (LSIL), 22 high grade (HSIL) squamous intraepithelial lesions, 28 invasive (13 stage I and 15 stage II-IV) squamous cell carcinoma (SCC) and 15 benign cervices were immunohistochemically studied for involvement of Bcl-2 and Bax proteins in cervical carcinogenesis.
  • Bcl-2 was upregulated (p < 0.05) in HSIL and Bax in SCC when compared with benign cervical squamous epithelium.
  • Bcl-2 expression was confined to the lower third of the epithelium in the benign cervices and LSIL.
  • SCCs showed "diffuse" (evenly distributed) or "basal" (intensified staining around the periphery of the invading tumour nests) expression of Bcl-2.
  • Of the 5 SCCs with upregulated Bcl-2, 1 of 2 (50%) stage I and 3 (100%) stage II-IV tumours exhibited the "basal" pattern.
  • Benign cervical squamous epithelium, LSIL, HSIL and SCC showed a generally diffuse Bax expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Uterine Cervical Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694953.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


63. Miwa K, Taniguchi Y, Adachi Y, Haruki T, Nakamura H: [Huge mediastinal mature teratoma with combined resection of adjacent structures; report of a case]. Kyobu Geka; 2006 Nov;59(12):1115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 64-year-old woman with an anterior mediastinal tumor on a chest computed tomography (CT) before operation of uterine cancer.
  • After the radical surgery and a chemotherapy for uterine cancer, surgical resection of mediastinal tumor was performed in July 2005 because of gradually progression in tumor size.
  • Under the median sternotomy, the tumor revealed intensive adhesion to the right lung and the left brachiocephalic vein.
  • We performed a complete resection of the tumor with combined resection of adherent parts of them.
  • The tumor was 9 x 8 cm in size, containing with yellow cream-like fluid and hair.
  • Histologically, the tumor was diagnosed as a mature teratoma with the tissue of bone, digestive tract epithelium, bronchial epithelium and so on.
  • In benign teratoma, it is not rare to perforate to the adjacent structures.
  • [MeSH-major] Brachiocephalic Veins / surgery. Lung Diseases / surgery. Mediastinal Neoplasms / surgery. Teratoma / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094553.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Mitmaker E, Alvarado C, Bégin LR, Trifiro M: Microsatellite instability in benign and malignant thyroid neoplasms. J Surg Res; 2008 Nov;150(1):40-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability in benign and malignant thyroid neoplasms.
  • The purpose of this study was to further define the distribution of MSI in both normal and neoplastic thyroid follicular epithelium.
  • DESIGN: Using laser capture microdissection, cells from both normal and tumor tissue were individually collected.
  • RESULTS: Forty benign and malignant thyroid tumors were compared with their adjacent normal thyroid follicular tissue and were analyzed for MSI.
  • For benign follicular adenomas, 9/10 demonstrated microsatellite stability or low-frequency MSI.
  • More importantly, the technique of laser capture microdissection allows for more accurate selection of benign, malignant, and normal DNA.
  • [MeSH-major] Carcinoma, Papillary / pathology. DNA Mismatch Repair. DNA, Neoplasm / chemistry. Microsatellite Instability. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243241.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


65. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


66. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP: Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol; 2006 Jan;13(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review addresses a multitude of epithelial changes; benign, malignant, and an intriguing third group, which we term "p53 signatures," is found in benign, nonciliated epithelium and stain intensely positive for p53.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Proliferation. Epithelium / chemistry. Epithelium / pathology. Fallopian Tubes / chemistry. Fallopian Tubes / cytology. Fallopian Tubes / pathology. Female. Gene Expression Regulation, Neoplastic. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Humans. Ovariectomy. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462151.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 31
  •  go-up   go-down


67. Ram R: Ameloblastoma relapse after 16 years of resection in symphysis of mandible sparing the bone graft. Natl J Maxillofac Surg; 2010 Jul;1(2):190-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a tumor derived from epithelium involved in odontogenesis.
  • Although it is considered a benign tumor, its clinical behavior may be regarded as lying between benign and malignant.
  • The challenges in the management of this tumor are to provide complete excision as recurrence may occur in incomplete removal and also to reconstruct the bony defect in order to give reasonable cosmetic and functional outcome to the patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22442598.001).
  • [ISSN] 2229-3418
  • [Journal-full-title] National journal of maxillofacial surgery
  • [ISO-abbreviation] Natl J Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3304200
  • [Keywords] NOTNLM ; Ameloblastoma relapse / epithelial odontogenic tumor / mandibular reconstruction
  •  go-up   go-down


68. Manucha V, Sun CC: Cytologic findings and differential diagnosis in hepatic Epithelioid hemangioendothelioma: a case report. Acta Cytol; 2008 Nov-Dec;52(6):713-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epithelioid hemangioendothelioma is a rare tumor of vascular origin with nonspecific clinical and radiologic presentation.
  • CASE: We describe a rare case of unifocal, hepatic hemangioendothelioma in a 47-year-old woman; a broad differential diagnosis of malignant neoplasm was considered during on-site evaluation of fine needle aspiration (FNA); diagnosis was made on subsequent core biopsy.
  • To better describe the cytologic findings, FNA was performed on the resected tumor.
  • The cytologic feature of this tumor, comparison with histol ogy findings and the differential diag nosis are discussed in detail.
  • The smears are characterized by a discohesive population of atypical cells in a clean background, fragments of metachromatic stroma, scattered benign hepatocytes and bile duct epithelium.

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068677.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Cil AP, Atasoy P, Kara SA: Myometrial involvement of tumor-like cystic endosalpingiosis: a rare entity. Ultrasound Obstet Gynecol; 2008 Jul;32(1):106-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myometrial involvement of tumor-like cystic endosalpingiosis: a rare entity.
  • Endosalpingiosis is characterized by the presence of benign glands lined by tubal-type epithelium involving the pelvic and lower abdominal peritoneum and pelvic and para-aortic lymph nodes in women.
  • Rarely, cystification can occur, resulting in a neoplasm-like mass associated with clinical manifestations, an intraoperative abnormality, or a striking finding on gross examination.
  • Clinicians should be aware of this type of uterine benign manifestation so as to refrain from overtreatment.
  • [MeSH-major] Cysts / diagnosis. Myometrium. Uterine Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570219.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  •  go-up   go-down


70. Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D: Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch; 2005 Jul;447(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases.
  • We found that 78% of malignant and 75% of benign cases showed iNOS immunoreactivity.
  • However, the intensity and the quantity of iNOS expression were significantly higher in the cancer group when compared with benign breasts (P<0.001), suggesting a role of iNOS in breast carcinogenesis.
  • We were unable to show a correlation between iNOS expression and tumor grade, axillary lymph node status, and estrogen receptor expression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Jun;14(6):1069-73 [10339659.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):222-9 [10219017.001]
  • [Cites] APMIS. 2003 Dec;111(12):1137-46 [14678024.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1191-8 [12216084.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):145-51 [10573107.001]
  • [Cites] Urol Oncol. 2003 Mar-Apr;21(2):117-22 [12856639.001]
  • [Cites] Cancer. 1998 May 15;82(10):1897-903 [9587122.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):662-6 [11193479.001]
  • [Cites] Hypertension. 1994 Jun;23(6 Pt 2):1121-31 [7515853.001]
  • [Cites] Acta Neuropathol. 2003 Apr;105(4):333-40 [12624786.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):634-5 [11002770.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):880-6 [10970689.001]
  • [Cites] Scand J Gastroenterol. 2000 Nov;35(11):1204-11 [11145294.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):725-8 [14991947.001]
  • [Cites] Am Surg. 2001 Jul;67(7):709-13 [11450795.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):30-9 [10728591.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4768-75 [11156233.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Oct;32(5):534-8 [14759114.001]
  • [Cites] Asian J Surg. 2004 Jan;27(1):10-7 [14719508.001]
  • [Cites] BJU Int. 2000 Aug;86(3):234-9 [10930922.001]
  • [Cites] Lab Invest. 1999 Oct;79(10):1215-25 [10532585.001]
  • [Cites] Essays Biochem. 1997;32:61-72 [9493011.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):521-4 [11956620.001]
  • [Cites] Ai Zheng. 2003 Sep;22(9):978-81 [12969533.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):619-23 [12943630.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):265-71 [15661552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):217-21 [12909236.001]
  • [Cites] Arch Surg. 1999 Mar;134(3):245-51 [10088562.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Aug;17(8):914-21 [12164968.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Ann Anat. 2003 Dec;185(6):549-54 [14704000.001]
  • [Cites] J Zhejiang Univ Sci. 2003 Mar-Apr;4(2):221-7 [12659238.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):534-41 [9716040.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2408-16 [10873093.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):1084-8 [12160278.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):109-14 [10755599.001]
  • (PMID = 15947943.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


71. Rodriguez FJ, Aubry MC, Tazelaar HD, Slezak J, Carney JA: Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol; 2007 Dec;31(12):1844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma.
  • The Carney triad is the clinical association of gastric stromal sarcomas, pulmonary cartilaginous tumors, and extra-adrenal paragangliomas.
  • The pulmonary tumors are its second commonest component and have been misinterpreted clinically and pathologically as metastases from the gastric tumors and pulmonary cartilaginous hamartomas, respectively.
  • Forty-two patients with pulmonary cartilaginous tumors as a component of Carney triad were identified.
  • Hematoxylin and eosin-stained sections of the neoplasms were evaluated for a series of histologic features.
  • A subgroup of 41 tumors from the latter was compared with those in a group of pulmonary cartilaginous hamartomas.
  • Their pulmonary neoplasm(s) were usually asymptomatic, often multiple, well circumscribed, medium-sized (mean diameter=2.8 cm), and composed almost exclusively of cartilage and bone surrounded by a fibrous pseudocapsule.
  • They showed no fat, smooth muscle or entrapped respiratory epithelium, tissues that were common in pulmonary hamartoma (P<0.0001).
  • None of the tumors metastasized or was fatal.
  • The pulmonary neoplasms in the Carney triad are well-differentiated benign cartilaginous tumors that are best designated as chondromas.
  • They differ pathologically from pulmonary cartilaginous hamartomas on the basis of the presence of a thin fibrous pseudocapsule, frequent bone metaplasia, and calcification, and also the absence of entrapped epithelium and fat.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Paraganglioma, Extra-Adrenal / pathology

  • Genetic Alliance. consumer health - Chondroma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043038.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


73. Mukhopadhyay S, Raha K, Mondal SC: Huge ameloblastoma of jaw-A case report. Indian J Otolaryngol Head Neck Surg; 2005 Jul;57(3):247-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a tumor of odontogenic epithelium.
  • It is a tumour of intermediate malignant potential which lies in the gray zone between benign and malignant neoplasm.
  • A huge ameloblastoma revealing benign cytological features in FNAC is being reported.Ameloblastoma arises from odontogenic epithelium.
  • This tumor can occur at any age.
  • This tumor shows invasive property and a remarkable tendency of recurrence.
  • Ameloblastic carcinoma is a tumor with microscopic features of ameloblastoma that displays malignant features at cytological level.([2]) It usually has aggressive course.
  • A case of large ameloblastoma with slow clinical course and benign cytological as well as histological features is being reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1984 Feb;57(2):168-76 [6366686.001]
  • (PMID = 23120181.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451340
  •  go-up   go-down


74. Rufforny I, Wilkinson EJ, Liu C, Zhu H, Buteral M, Massoll NA: Human papillomavirus infection and p16(INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. J Low Genit Tract Dis; 2005 Apr;9(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 49 vulvar biopsy samples were examined by hematoxylin-eosin staining from benign/reactive lesions, condyloma acuminatum, VIN, and invasive squamous cell carcinoma (SCC).
  • No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions.
  • In addition, none of the benign/reactive or condyloma lesions were positive for HPV type 16 by RT-PCR analysis.
  • CONCLUSIONS: Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) negative.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Papillomavirus Infections / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Viral / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Papillomaviridae / genetics. Polymerase Chain Reaction. Vulva / chemistry. Vulva / pathology. Vulva / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870532.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


75. Xuan Q, Yang X, Mo L, Huang F, Pang Y, Qin M, Chen Z, He M, Wang Q, Mo ZN: Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer. Arch Pathol Lab Med; 2008 Nov;132(11):1796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: The mRNA expression of KLK7 and ALP transcript in benign prostate epithelial cells and prostate cancers was evaluated by semiquantitative reverse transcription-polymerase chain reaction.
  • We examined hK7 and ALP protein expression by immunohistochemistry in 20 normal prostate tissues, 50 benign prostatic hyperplasia tissues, and 103 prostate cancers.
  • Western blot examination showed protein expression of hK7 and ALP in benign prostate epithelial cells and prostate cancer cell lines.
  • RESULTS: Semiquantitative polymerase chain reaction examination revealed that the mRNA level of KLK7 and ALP was significantly decreased in prostate cancers compared with that in benign prostate epithelial cells (P < .001).
  • Immunohistochemical expression of hK7 was observed in prostate epithelial cells, whereas little or no staining was observed in prostate cancer.
  • Western blot analysis revealed that hK7 and ALP were decreased in malignant prostate epithelium.
  • [MeSH-minor] Case-Control Studies. Cell Line, Tumor. Down-Regulation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Male. Prostate / cytology. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976018.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Secretory Leukocyte Peptidase Inhibitor; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


76. Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH: p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol; 2005 Dec;18(12):1527-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study.
  • Breast phyllodes tumors are fibroepithelial neoplasms whose clinical behavior is difficult to predict on histology.
  • In this study, we determined if p53 and CD117 (c-kit) protein expression was predictive of behavior in a series of 335 phyllodes tumors diagnosed at the Singapore General Hospital, using immunohistochemistry on tissue microarrays.
  • Representative areas from 250 (75%) benign, 54 (16%) borderline and 31 (9%) malignant phyllodes tumors were selected for construction of tissue microarrays using the 2 mm punch.
  • Staining proportion and intensity of both epithelial and stromal elements were analyzed. p53 immunostaining was observed in the epithelium of 28 (10%) of 278 microarrays; myoepithelium of 53 (21%) of 251 microarrays; and stromal cells in 105 (36%) of 289 microarrays.
  • CD117 immunohistochemical reactivity was noted in epithelial and stromal components of 175 (of 267, 66%) and 17 (of 273, 6%) microarrays, respectively.
  • Stromal p53 and CD117 protein expression was associated with tumor grade (P < 0.05).
  • We conclude that tissue microarrays are a convenient method for evaluating immunostaining results of large numbers of phyllodes tumors.
  • Although positive p53 stromal immunohistochemical detection may corroborate histologic malignancy, it is CD117 protein expression in phyllodes tumor stromal cells that may be of potential utility in predicting recurrent disease.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. Tissue Array Analysis / methods. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258510.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


77. Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A, Bagasra O, Costello LC: hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer; 2005 Sep 09;4:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The normal peripheral zone glandular epithelium has the unique function of accumulating high levels of zinc.
  • The lost ability of the neoplastic epithelial cells to accumulate zinc is a consistent factor in their development of malignancy.
  • RESULTS: hZIP1 gene expression, ZIP1 transporter protein, and cellular zinc were prominent in normal peripheral zone glandular epithelium and in benign hyperplastic glands (also zinc accumulating glands).
  • In contrast, hZIP1 gene expression and transporter protein were markedly down-regulated and zinc was depleted in adenocarcinomatous glands and in prostate intra-epithelial neoplastic foci (PIN).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. CITRIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7 [12829793.001]
  • [Cites] Prostate. 1999 Aug 1;40(3):200-7 [10398282.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):253-60 [12966353.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):187-95 [14568174.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2258-62 [14634392.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):546-55 [14760076.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):374-81 [14968438.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:316-20 [15033742.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13293-6 [14966140.001]
  • [Cites] Eur Urol. 2004 Jun;45(6):683-91 [15149739.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(2):111-7 [15175662.001]
  • [Cites] J Physiol. 2004 Jun 15;557(Pt 3):719-31 [15090606.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):134-40 [15361710.001]
  • [Cites] Cancer Res. 1967 Aug;27(8):1348-53 [4167368.001]
  • [Cites] Invest Urol. 1969 Jan;6(4):345-7 [5773519.001]
  • [Cites] Exp Mol Pathol. 1973 Oct;19(2):139-42 [4127820.001]
  • [Cites] Br J Cancer. 1979 Jun;39(6):700-4 [87214.001]
  • [Cites] Urol Res. 1982;10(6):301-3 [6186062.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1388-92 [2465818.001]
  • [Cites] Biochem Soc Trans. 2005 Feb;33(Pt 1):237-40 [15667316.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3028-35 [15687339.001]
  • [Cites] Front Biosci. 2005;10:2230-9 [15970489.001]
  • [Cites] Mitochondrion. 2005 Jun;5(3):143-53 [16050980.001]
  • [Cites] Mol Cell Biochem. 2005 Dec;280(1-2):1-8 [16511951.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5560-4 [10681536.001]
  • [Cites] J Inorg Biochem. 2000 Jan 30;78(2):161-5 [10766339.001]
  • [Cites] Mol Urol. 2000 Spring;4(1):31-6 [10851304.001]
  • [Cites] Am J Hum Genet. 2000 Dec;67(6):1367-75 [11067781.001]
  • [Cites] Oncology. 2000 Nov;59(4):269-82 [11096338.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):311-8 [12210492.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):451-63 [12353259.001]
  • [Cites] Radiology. 1996 Mar;198(3):795-805 [8628874.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):28875-81 [9360955.001]
  • [Cites] Int Urol Nephrol. 1997;29(5):565-74 [9413764.001]
  • [Cites] Prostate. 1998 Jun 1;35(4):285-96 [9609552.001]
  • [Cites] Prostate. 1999 Feb 15;38(3):237-45 [10068348.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17499-504 [10364181.001]
  • [Cites] J Inorg Biochem. 2003 Aug 1;96(2-3):435-42 [12888280.001]
  • (PMID = 16153295.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R01-097714; United States / NCI NIH HHS / CA / CA 79903; United States / NCI NIH HHS / CA / R01 CA079903; United States / NCI NIH HHS / CA / R01 CA071207; United States / NCI NIH HHS / CA / CA 71207
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 0 / RNA, Messenger; 0 / SLC39A1 protein, human; 2968PHW8QP / Citric Acid; J41CSQ7QDS / Zinc
  • [Other-IDs] NLM/ PMC1243239
  •  go-up   go-down


78. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


79. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


80. Hyun DN, Won JH, Park JS, Chung H: A Case of Steatocystoma Simplex Involving the Scalp. Ann Dermatol; 2008 Dec;20(4):230-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steatocystoma is a benign adnexal tumor originating from the pilosebaceous duct junction which can be classified into two groups (steatocystoma simplex and steatocystoma multiplex).
  • A 49-year-old man presented for evaluation and treatment of a solitary papule on the right parietal scalp which had persisted for a period of 1 year.
  • The histopathologic examination revealed a thin-walled cyst consisting of stratified squamous epithelium with hyaline cuticle that lacked a stratum granulosum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27303199.001).
  • [ISSN] 1013-9087
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4903986
  • [Keywords] NOTNLM ; Scalp / Steatocystoma simplex
  •  go-up   go-down


81. Pontes HA, Pontes FS, Silva BS, Cury SE, Fonseca FP, Salim RA, Pinto Júnior Ddos S: Immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in a case of ameloblastic fibrosarcoma. Ann Diagn Pathol; 2010 Dec;14(6):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibrosarcoma (AFS), regarded as the malignant counterpart of the benign ameloblastic fibroma, is an extremely rare odontogenic neoplasm with only 68 cases reported in the English literature up to 2009.
  • It is composed of a benign odontogenic epithelium, resembling that of ameloblastoma, and a malignant mesenchymal part exhibiting features of fibrosarcoma.
  • Due to the rarity of the lesion, little is known about its molecular pathogenesis; therefore, in the current study, we sought to evaluate the immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in AFS, comparing the results obtained with its benign counterpart, as well as to report a new case of this rare entity affecting a 19-year-old female patient.
  • [MeSH-major] Fibrosarcoma / metabolism. Ki-67 Antigen / metabolism. Mandibular Neoplasms / metabolism. Odontogenic Tumors / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adult. Ameloblasts / metabolism. Ameloblasts / pathology. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074695.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


82. Brooks MD, Bennett RD, Strehler EE, Sebo TJ, Eckert SE, Carr AB: Human calmodulin-like protein (CLP) expression in oral squamous mucosa and in malignant transformation. J Prosthodont; 2009 Jan;18(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These samples demonstrated regions of normal epithelial cells as well as invasive squamous cell carcinoma.
  • One normal breast epithelial sample was also obtained for positive control.
  • Staining patterns and intensity were noted in normal oral mucosa, comparing them to the normal breast epithelium sample.
  • Staining patterns and intensity were then observed in squamous tumor cells, comparing them to the patterns of benign squamous mucosa.
  • The staining intensity was equivalent to the staining seen in the benign breast epithelium used as a control.
  • There was a sharp contrast in staining quality and clarity between benign and malignant tissue.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166543.001).
  • [ISSN] 1532-849X
  • [Journal-full-title] Journal of prosthodontics : official journal of the American College of Prosthodontists
  • [ISO-abbreviation] J Prosthodont
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CALML3 protein, human; 0 / Calmodulin
  •  go-up   go-down


83. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


84. Liu X, Ma YQ, Wang J: [Prepubertal-type vulva fibroma: a clinicopathological study of two cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grossly, cut surface of the tumor appeared as the gray fibrous tissue without any definited lump detected.
  • The tumor cells extended downward under the epithelium and infiltrated between the fat tissue, nerve fibers as well as the capillaries making a lesion looked somewhat like a harmatoma.
  • CONCLUSIONS: PVF is a benign mesenchymal lesion with a predilection of involving the vulva of prepubertal girls or adults in rare cases.
  • Approximately one third of the tumors develop local recurrence due to incomplete excision, however, there is also occasionally spontaneous regression.
  • [MeSH-minor] Antigens, CD34 / metabolism. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Myxoma / pathology. Neoplasm Recurrence, Local. Vulva / pathology. Vulva / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388398.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vimentin
  •  go-up   go-down


85. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers; 2010 Jul-Sep;25(3):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
  • Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos.
  • We measured OPN in 239 plasma samples from 207 asbestos-exposed subjects including 94 healthy controls and 113 subjects with BRD, and 32 patients with epithelial MPM, employing a commercially available ELISA.
  • Plasma and serum OPN levels were significantly higher (p<0.0001) in patients with epithelial MPM than in the healthy control group and the BRD group.
  • Plasma and serum OPN may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood. Specimen Handling
  • [MeSH-minor] Aged. Blood Preservation / methods. Blood Specimen Collection. Cryopreservation. Enzyme-Linked Immunosorbent Assay. Epithelium / pathology. Female. Humans. Male. Middle Aged. Occupational Diseases / blood. Occupational Diseases / etiology. Occupational Exposure. Plasma. Respiration Disorders / blood. Serum. Smoking / blood. Temperature

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878622.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


86. Yang JH, Shi YF, Cheng Q, Deng L: Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecol Oncol; 2006 Feb;100(2):294-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of aquaporin-5 in the epithelial ovarian tumors.
  • OBJECTIVE: To investigate the expression and localization of aquaporin-5 (AQP5) in epithelial ovarian tumors and its clinic significance.
  • METHODS: The expression of AQP5 protein and mRNA in 65 cases epithelial ovarian tumors and 13 cases normal tissue were measured by immunohistochemical technique, Western blotting and RT-PCR, respectively.
  • RESULTS: AQP5 is mainly localized in the basolateral membranes of benign tumor cells, the apical and basolateral membrane of borderline cells and scattered in the membrane of malignant cells and almost no or weak staining in normal ovarian epithelium.
  • The AQP5 expression in ovarian malignant and borderline tumors was significantly higher than that of benign tumors (P < 0.05) and normal tissue (P < 0.05).
  • Of all the epithelial ovarian malignant tumors, the AQP5 expression in cases with ascites volume more than 1000 ml was higher than that of ascites volume less than 500 ml (P < 0.05).
  • CONCLUSION: The data suggest that overexpression of AQP5 play an important role in tumorigenesis of epithelial ovarian tumors, which may be related to the ascites formation of ovarian carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Ascites / metabolism. Ascites / pathology. Blotting, Western. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242760.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP5 protein, human; 0 / Aquaporin 5; 0 / RNA, Messenger
  •  go-up   go-down


87. Woenckhaus M, Grepmeier U, Wild PJ, Merk J, Pfeifer M, Woenckhaus U, Stoelcker B, Blaszyk H, Hofstaedter F, Dietmaier W, Hartmann A: Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium. Am J Clin Pathol; 2005 May;123(5):752-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium.
  • Multitarget fluorescence in situ hybridization (FISH; LAVysion, Vysis, Downers Grove, IL) targeting chromosomes 6p11-q11, 7p12, 8q24, and 5p15.2 was compared with results of microsatellite studies at chromosome 3p to identify molecular changes associated with tobacco use and tumor development in non-small cell lung cancer (NSCLC).
  • Analyses were performed on 26 NSCLCs and matched benign bronchial epithelium; samples from 10 patients without NSCLC served as control samples.
  • Significant molecular differences between tumor tissue and corresponding benign bronchi were found using FISH (P = .001) and loss of heterozygosity (LOH) analysis (P = .031).
  • Bronchial epithelium from patients with NSCLC was genetically different from epithelium from patients without NSCLC in FISH analysis (P = .025).
  • Receiver operating characteristic curve analysis revealed an optimal cutoff value of 5% atypical cells for bronchial epithelium.
  • Multicolor FISH analysis is able to detect a tumor-associated molecular field effect in bronchi adjacent to NSCLC.
  • [MeSH-minor] Adult. Aged. Cell Count. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Humans. Male. Microsatellite Repeats. Middle Aged. ROC Curve


88. Fujimura T, Takahashi S, Urano T, Kumagai J, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Inoue S: Increased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer. Int J Cancer; 2007 Jun 1;120(11):2325-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expressions of ERRalpha in cancerous lesions (n = 106) and benign foci (n = 99) of 106 surgically obtained prostate specimens were evaluated by immunohistochemistry.
  • Positive immunostaining of ERRalpha in the nuclei was found in 73 (69%) cancerous and 47 (47.5%) benign epithelium, whereas the stromal tissues were negative for ERRalpha.
  • The mean immunoreactivity score (IR score) of the cancerous lesions (3.5 +/- 2.6) was significantly higher than that of the benign foci (1.8 +/- 2.1) (p < 0.0001).
  • [MeSH-minor] Aged. Cell Line, Tumor. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294452.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ERRalpha estrogen-related receptor; 0 / Receptors, Estrogen
  •  go-up   go-down


89. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
  • Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood.
  • This has led to the proposal that ovarian cancer develops de novo.
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features.
  • One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas.
  • These tumors generally behave in an indolent fashion, are confined to the ovary at presentation and, as a group, are relatively genetically stable.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • In contrast, another group of tumors, designated type II, is highly aggressive, evolves rapidly and almost always presents in advanced stage.
  • Type II tumors include conventional high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal tumors (carcinosarcoma).
  • They displayTP53 mutations in over 80% of cases and rarely harbor the mutations that are found in the type I tumors.
  • Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.
  • Endometrioid and clear cell tumors have been associated with endometriosis that is regarded as the precursor of these tumors.
  • Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia.
  • Appreciation of these new concepts will allow for a more rationale approach to screening, treatment, and prevention that potentially can have a significant impact on reducing the mortality of this devastating disease.


90. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


91. Xian W, Miron A, Roh M, Semmel DR, Yassin Y, Garber J, Oliva E, Goodman A, Mehra K, Berkowitz RS, Crum CP, Quade BJ: The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol; 2010 Jan;220(1):17-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A candidate early precursor to pelvic serous cancer, the 'p53 signature', is commonly found in the benign mucosa of the distal Fallopian tube and harbours p53 mutations and evidence of DNA damage.
  • LFS tubal epithelium contained abundant (10-20 per section) p53 signatures with evidence of DNA damage and low proliferative activity.
  • Six of 11 LFS microdissected p53 signatures (55%) and 15 of 21 serous carcinomas (71%) revealed LOH at the p53 locus, relative to background epithelium.
  • The LFS model confirms prior observations that the distal Fallopian tube is particularly prone to focal epithelial p53 gene inactivation-p53 mutation and LOH-in the absence of malignancy or increased epithelial proliferation.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Mol Med Today. 1997 Sep;3(9):390-5 [9302689.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Cell. 2007 May 4;129(3):523-36 [17482546.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] BMC Cancer. 2008;8:17 [18208621.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1337-44 [18483220.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Pediatr Radiol. 2009 Feb;39 Suppl 1:S27-31 [19083227.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):731-5 [19221485.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3625-33 [19336573.001]
  • [Cites] Histopathology. 2001 May;38(5):481-2 [11422490.001]
  • [Cites] In Vivo. 1999 Jan-Feb;13(1):99-106 [10218141.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Fam Cancer. 2009;8(4):339-46 [19340607.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):787-95 [11550149.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):157-62 [11905807.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [CommentIn] J Pathol. 2010 Jan;220(1):5-6 [19882674.001]
  • (PMID = 19834951.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / 1R21CA124688-01A1; United States / NCI NIH HHS / CA / P50CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS184416; NLM/ PMC2841524
  •  go-up   go-down


92. Djordjevic B, Hanna WM: Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Mod Pathol; 2008 Oct;21(10):1238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations.
  • We examined stromal c-kit expression by immunohistochemistry in 68 cases comprising fibroadenomas, fibroadenomas with cellular stroma, and benign, borderline, and malignant phyllodes tumors.
  • Membrane staining was identified in the epithelium of 82% of cases, representing all diagnostic categories in the study.
  • One borderline and one malignant phyllodes tumor showed a diffuse weak stromal signal, which could not be accounted for by toluidine blue and tryptase.
  • C-kit, therefore, has neither a diagnostic nor a prognostic role in phyllodes tumors, and there is no rationale for the treatment of recurrent of malignant phyllodes tumor patients with tyrosine kinase inhibitors.
  • [MeSH-major] Breast Neoplasms / metabolism. Mast Cells / metabolism. Phyllodes Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Mastectomy. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500266.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


93. Policarpio-Nicolas ML, Shami VM, Kahaleh M, Adams RB, Mallery S, Stanley MW, Bardales RH, Stelow EB: Fine-needle aspiration cytology of pancreatic lymphoepithelial cysts. Cancer; 2006 Dec 25;108(6):501-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphoepithelial cysts (LECs) of the pancreas are extremely rare, benign, nonneoplastic cysts that can mimic pseudocysts or cystic neoplasms clinically and radiographically.
  • The cytologic features of LECs have been described only in a handful of case reports and may overlap with both benign and malignant pancreatic tumors.
  • Tumor sizes ranged from 1.8 cm to 5.7 cm in greatest dimension.
  • Smears from all patients revealed numerous anucleated squamous cells, rare benign nucleated cells, amorphous debris, and an absence of lymphocytes.
  • Mildly atypical mucinous glandular and parakeratotic epithelium were identified in 2 patients, leading to diagnoses of atypical and suspicious for malignancy.
  • [MeSH-major] Lymphocele / complications. Neoplasms, Glandular and Epithelial / diagnosis. Pancreatic Cyst / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063496.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


94. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


95. Bologna-Molina R, Mosqueda-Taylor A, de Almeida-Oslei P, Toral-Rizo V, Martínez-Mata G: Peripheral desmoplastic ameloblastoma: histopathological and immunohistochemical profile of a case. Med Oral Patol Oral Cir Bucal; 2010 Nov;15(6):e846-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reports a new case of this unusual neoplasm in a 66 year-old woman in which the main complaint was an asymptomatic swelling located in the right body of mandible.
  • Histopathological findings were similar to the two previously reported cases of this tumor.
  • Positive immunohistochemical stain for laminin V and type IV collagen suggests an inductive effect of the epithelium over the stroma while the low index of p53 protein and Ki-67 expression in epithelium and stromal cells, as well as CD138 uniform positive-stain in epithelial cells, support the benign biological behavior of this lesion.
  • Including this new case, currently there are only three reports of this rare neoplasm.
  • Reports of new cases of peripheral desmoplastic ameloblastoma are necessary for a better understanding of the origin and behavior of this particular subtype of ameloblastoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526273.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


96. Hansen T, Kirkpatrick CJ: Expression of podoplanin in Warthin tumours. Oral Maxillofac Surg; 2010 Dec;14(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of podoplanin in Warthin tumours.
  • PURPOSE: Warthin tumour is the second most common benign tumour of the parotid gland.
  • This study was designed to investigate the lymphatic vessels in Warthin tumours in an effort to understand better its pathogenesis.
  • MATERIALS AND METHODS: Tissue specimens of 31 patients (19 men and 11 women; mean age 57 years, median size of the tumours 2.86 cm) were analysed by means of immunohistochemistry applying the monoclonal antibody D2-40.
  • CONCLUSIONS: Since subcapsular sinuses are a major morphological feature of lymph nodes in general, the finding of podoplanin expression in the large majority of subcapsular vessels in Warthin tumours confirms the view that this tumour has its origin in regional lymph nodes.
  • [MeSH-major] Adenolymphoma / pathology. Biomarkers, Tumor / analysis. Membrane Glycoproteins / analysis. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Endothelial Cells / pathology. Endothelium, Lymphatic / pathology. Epithelium / pathology. Female. Humans. Immunohistochemistry. Lymphatic Vessels / pathology. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Oral Biol. 2008 Sep;53(9):835-41 [18339356.001]
  • [Cites] Virchows Arch. 2007 Apr;450(4):449-53 [17377811.001]
  • [Cites] Pathologe. 2004 Sep;25(5):362-74 [15164222.001]
  • [Cites] Oral Oncol. 2007 Jul;43(6):614-8 [16996778.001]
  • [Cites] Histopathology. 2005 Apr;46(4):396-402 [15810951.001]
  • [Cites] Histopathology. 2001 Oct;39(4):347-52 [11683933.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 May;18(3):226-30 [20042851.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):232-6 [11175641.001]
  • (PMID = 20411288.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / monoclonal antibody D2-40
  •  go-up   go-down


97. Andikyan V, Taylor HS: WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type. J Cell Mol Med; 2009 Nov-Dec;13(11-12):4522-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type.
  • The homeobox gene HOXA10 controls uterine organogenesis during embryonic development and similarly is expressed in endometroid epithelial ovarian cancer.
  • Here we confirmed aberrant regulation of HOXA10 expression in epithelial uterine and ovarian carcinomas.
  • We identified a HOXA10 epithelial regulatory element containing an enhancer that drove HOXA10 expression specifically in gynaecologic epithelium.
  • We further identified an adjoining dominant repressor element that restricted regulation by the epithelial enhancer to a subset of epithelial cell types.
  • We identified a strong inverse correlation between HOXA10 expression and that of the Wilms' Tumour 1 (WT1) gene in multiple benign and malignant gynaecologic tissues, suggesting functionality of the WT1 sites in the repressor.
  • Mutation of the two WT1 binding sites abolished WT1 binding to the element as well as the ability to affect epithelial enhancer activity in reporter assays.
  • This suggests that Gynaecologic epithelial histologic type is regulated by WT1 expression through its selective repression of HOX genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Endocrinology. 2004 May;145(5):2291-6 [14726435.001]
  • [Cites] Nature. 1978 Dec 7;276(5688):565-70 [103000.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Cell. 1992 Jan 24;68(2):283-302 [1346368.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2445-53 [1358259.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2141-9 [1331933.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Cell. 1994 Jul 29;78(2):191-201 [7913880.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):460-3 [7700356.001]
  • [Cites] Development. 1995 May;121(5):1373-85 [7789268.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):284-9 [8673126.001]
  • [Cites] Dev Dyn. 1997 Apr;208(4):454-65 [9097018.001]
  • [Cites] Biol Reprod. 1997 Dec;57(6):1338-45 [9408238.001]
  • [Cites] Hum Mol Genet. 1998 Apr;7(4):709-14 [9499425.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1379-84 [9525980.001]
  • [Cites] Curr Opin Genet Dev. 1998 Aug;8(4):423-9 [9729718.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1328-31 [10325287.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):522-8 [15494461.001]
  • [Cites] Nat Med. 2005 May;11(5):531-7 [15821746.001]
  • [Cites] Pediatrics. 2005 Oct;116(4):984-8 [16199712.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2428-37 [16199152.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):889-97 [16424022.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 15;58(12):1851-7 [10591139.001]
  • [Cites] Reprod Sci. 2007 Sep;14(6):605-14 [17959889.001]
  • [Cites] Semin Reprod Med. 2000;18(1):81-9 [11299523.001]
  • [Cites] Pediatr Nephrol. 2001 Apr;16(4):335-9 [11354777.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):111-3 [12932885.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):568-72 [15044858.001]
  • (PMID = 19017365.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD036887; United States / NICHD NIH HHS / HD / R29 HD036887; United States / NICHD NIH HHS / HD / U54 HD052668-05; United States / NICHD NIH HHS / HD / U54 HD052668; United States / NICHD NIH HHS / HD / HD062668; United States / NICHD NIH HHS / HD / R01 HD036887
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Repressor Proteins; 0 / WT1 Proteins; 140441-81-2 / HOXA10 protein, human
  • [Other-IDs] NLM/ NIHMS293627; NLM/ PMC3107857
  •  go-up   go-down


98. Magro G, Greco P, Alaggio R, Gangemi P, Ninfo V: Polypoid angiomyofibroblastoma-like tumor of the oral cavity: a hitherto unreported soft tissue tumor mimicking embryonal rhabdomyosarcoma. Pathol Res Pract; 2008;204(11):837-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid angiomyofibroblastoma-like tumor of the oral cavity: a hitherto unreported soft tissue tumor mimicking embryonal rhabdomyosarcoma.
  • We report on a previously unrecognized fibro-myofibroblastic tumor in the oral cavity of a 15-year-old girl.
  • Morphologically, the tumor mimicked a rhabdomyosarcoma, botryoid variant.
  • These cells were separated from the overlying squamous epithelium by a rim of fibrous stroma.
  • The tumor contained abundant small- to medium-sized, thin-walled blood vessels without hyalinization.
  • The presence of these collagen mats and the expression of desmin, in association with no immunoreactivity to myogenin and MyoD1, were in keeping with the fibro-myofibroblastic nature of the tumor, excluding the diagnosis of embryonal rhabdomyosarcoma.
  • Regarding fibro-myofibroblastic tumors, we believe that the present case falls within the wide spectrum of benign stromal tumors, originally described in the lower female genital tract, but potentially occurring also at extragenital sites.
  • As morphological and immunohistochemical features were reminiscent of, but not identical with, angiomyofibroblastoma, the term "polypoid angiomyofibroblastoma-like tumor" is proposed.
  • Awareness and recognition of this tumor is crucial to avoid a diagnosis of malignancy.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656317.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Sharma V, Koirala K: Lateral rhinotomy vs mid-facial degloving for T3 inverted papilloma of nose and paranasal sinus. Nepal Med Coll J; 2009 Jun;11(2):115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papillomas are rare, benign epithelial tumours of the nasal cavity and paranasal sinuses.
  • All patients initially underwent nasal biopsy for confirmation of the diagnosis and pre-operative C.T. scan for tumour staging.
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968152.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


100. DeRoche TC, Hoschar AP, Hunt JL: Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas. Arch Pathol Lab Med; 2008 Dec;132(12):1907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas.
  • CONTEXT: Immunohistochemical stains for androgen receptor (AR), HER-2/neu, and p53 are used as diagnostic markers associated with malignancy in several histologic types of salivary gland tumors.
  • These markers may be useful in differentiating pleomorphic adenoma with cytologic atypia from intracapsular carcinoma ex pleomorphic adenoma (CXPA), as these tumors are often difficult to distinguish on the basis of morphology alone.
  • OBJECTIVE: To determine whether AR, HER-2/neu, and p53 expression can be seen in entirely benign pleomorphic adenomas.
  • DESIGN: Androgen receptor, HER-2/neu, and p53 immunoreactivity was assessed in 41 histologically and clinically benign pleomorphic adenomas.
  • The positive staining was mainly confined to the epithelial component, where the ductal epithelium showed no cytologic atypia.
  • Immunoreactivity for p53 was observed in the epithelial component of 5 of 41 cases, none of which stained for HER-2/neu and AR.
  • CONCLUSIONS: HER-2/neu, AR, and p53 are expressed in a subset of histologically and clinically benign pleomorphic adenomas.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Parotid Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Regulation. Humans. Male. Middle Aged. Retrospective Studies. Young Adult






Advertisement